Trastuzumab Deruxtecan in Previously Treated HER2-

New England Journal of Medicine
382, 610-621
DOI: 10.1056/nejmoa1914510

Citation Report

#	Article	IF	Citations
1	HER2-targeted agents overcome resistance. Nature Reviews Clinical Oncology, 2020, 17, 133-133.	12.5	6
2	Last but not least: antibodyâ€“drug conjugates in hormone receptor-positive metastatic breast cancer. Annals of Oncology, 2020, 31, 1594-1596.	0.6	1
3	Molecular Pathogenesis of Pancreatic Ductal Adenocarcinoma: Impact of miR-30c-5p and miR-30c-2-3p Regulation on Oncogenic Genes. Cancers, 2020, 12, 2731.	1.7	26
4	Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial. Annals of Oncology, 2020, 31, 1709-1718.	0.6	86
5	Trastuzumab Deruxtecan (DS-8201a): The Latest Research and Advances in Breast Cancer. Clinical Breast Cancer, 2021, 21, e212-e219.	1.1	39
6	Systemic therapy for metastatic HER2-positive breast cancer. Seminars in Oncology, 2020, 47, 259-269.	0.8	50
7	Clinical outcomes of patients with breast cancer relapsing after (neo)adjuvant trastuzumab and receiving trastuzumab rechallenge or lapatinib-based therapy: a multicentre retrospective cohort study. ESMO Open, 2020, 5, e000719.	2.0	5
8	Local and systemic treatment for HER2-positive breast cancer with brain metastases: a comprehensive review. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592095372.	1.4	12
9	Exaggerated Autophagy in Stanford Type A Aortic Dissection: A Transcriptome Pilot Analysis of Human Ascending Aortic Tissues. Genes, 2020, 11, 1187.	1.0	15
10	Antibodyâ€“Drug Conjugates for Cancer Therapy. Molecules, 2020, 25, 4764.	1.7	187
11	Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab. Cancers, 2020, 12, 3021.	1.7	6
12	5th ESO-ESMO international consensus guidelines for advanced breastÂcancer (ABC 5). Annals of Oncology, 2020, 31, 1623-1649.	0.6	761
13	An overview of antibodyâ€“drug conjugates in oncological practice. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592096299.	1.4	15
14	Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars. Drugs, 2020, 80, 1811-1830.	4.9	23
15	ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer. Cancers, 2020, 12, 1902.	1.7	29
16	Tailored Linker Chemistries for the Efficient and Selective Activation of ADCs with KSPi Payloads. Bioconjugate Chemistry, 2020, 31, 1893-1898.	1.8	13
17	Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With â‰¥ 2 HER2-Directed Regimens: Phase III NALA Trial. Journal of Clinical Oncology, 2020, 38, 3138-3149.	0.8	355
18	Improving Receptor-Mediated Intracellular Access and Accumulation of Antibody Therapeuticsâ€”The Tale of HER2. Antibodies, 2020, 9, 32.	1.2	15

#	Article	IF	Citations
19	ARX788, a Site-specific Anti-HER2 Antibodyâ€“Drug Conjugate, Demonstrates Potent and Selective Activity in HER2-low and T-DM1â€“resistant Breast and Gastric Cancers. Molecular Cancer Therapeutics, 2020, 19, 1833-1843.	1.9	81
20	Trial watch: IDO inhibitors in cancer therapy. OncoImmunology, 2020, 9, 1777625.	2.1	91
21	Biomarkers in Her2- Positive Disease. Breast Care, 2020, 15, 586-593.	0.8	8
22	Therapeutic Strategies for the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Positive (HR+/HER2+) Breast Cancer: A Review of the Current Literature. Cancers, 2020, 12, 3317.	1.7	19
23	Resistance and Overcoming Resistance in Breast Cancer . Breast Cancer: Targets and Therapy, 2020, Volume 12, 211-229.	1.0	50
24	Update Breast Cancer 2020 Part 4 â€“ Advanced Breast Cancer. Geburtshilfe Und Frauenheilkunde, 2020, 80, 1115-1122.	0.8	11
25	Breast Cancer Heterogeneity and Response to Novel Therapeutics. Cancers, 2020, 12, 3271.	1.7	40
26	Co-administered antibody improves penetration of antibodyâ€“dye conjugate into human cancers with implications for antibodyâ€“drug conjugates. Nature Communications, 2020, 11, 5667.	5.8	53
27	Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine. Geburtshilfe Und Frauenheilkunde, 2020, 80, 1134-1142.	0.8	4
28	Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany. BMC Cancer, 2020, 20, 1091.	1.1	1
29	Trastuzumab emtansine: a game changer in HER2-positive early breast cancer. Future Oncology, 2020, 16, 2595-2609.	1.1	3
30	The Evolving Landscape of HER2-Directed Breast Cancer Therapy. Current Treatment Options in Oncology, 2020, 21, 82.	1.3	17
31	Trastuzumab-deruxtecan: an investigational agent for the treatment of HER2-positive breast cancer. Expert Opinion on Investigational Drugs, 2020, 29, 901-910.	1.9	18
32	New drug approvals for 2019: Synthesis and clinical applications. European Journal of Medicinal Chemistry, 2020, 205, 112667.	2.6	36
33	Novel HER2â€“targeted therapies for HER2â€–positive metastatic breast cancer. Cancer, 2020, 126, 4278-4288.	2.0	103
34	The Changing Paradigm for the Treatment of HER2-Positive Breast Cancer. Cancers, 2020, 12, 2081.	1.7	71
35	Novel targeted therapies for metastatic breast cancer. Annals of Translational Medicine, 2020, 8, 907-907.	0.7	10
36	San Antonio Breast Cancer Symposium 2019: human epidermal growth factor receptorÂ2(HER2)-positive breast cancer and image-guided biopsy to detect pathologic complete response (pCR). Memo - Magazine of European Medical Oncology, 2020, 13, 341-345.	0.3	0

#	Article	IF	Citations
37	Antibodyâ€“drug conjugates to treat gastric cancer. Expert Opinion on Biological Therapy, 2021, 21, 923-930.	1.4	10
38	Antibodyâ€“drug conjugates in breast cancer: the chemotherapy of the future?. Current Opinion in Oncology, 2020, 32, 494-502.	1.1	25
39	Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2â€targeting Abâ€“drug conjugate, in monkeys. Cancer Science, 2020, 111, 4636-4645.	1.7	68
40	An overview of process development for antibody-drug conjugates produced by chemical conjugation technology. Expert Opinion on Biological Therapy, 2021, 21, 963-975.	1.4	42
41	Antibody-drug conjugates in metastatic triple negative breast cancer: a spotlight on sacituzumab govitecan, ladiratuzumab vedotin, and trastuzumab deruxtecan. Expert Opinion on Biological Therapy, 2021, 21, 903-913.	1.4	28
42	Prevention of brain metastases in human epidermal growth factor receptor 2-positive breast cancer. Current Opinion in Oncology, 2020, 32, 555-560.	1.1	4
43	Neratinib plus capecitabine for the treatment of advanced HER2-positive breast cancer. Expert Review of Anticancer Therapy, 2020, 20, 731-741.	1.1	6
44	An Overview of Antibody Conjugated Polymeric Nanoparticles for Breast Cancer Therapy. Pharmaceutics, 2020, 12, 802.	2.0	62
45	Management of brain metastases according to molecular subtypes. Nature Reviews Neurology, 2020, 16, 557-574.	4.9	104
46	<scp>HER2â€positive</scp> breast cancer brain metastasis: A new and exciting landscape. Cancer Reports, 2022, 5, e1274.	0.6	54
47	The Future of ER+/HER2â^' Metastatic Breast Cancer Therapy: Beyond PI3K Inhibitors. Anticancer Research, 2020, 40, 4829-4841.	0.5	21
48	HSP90 Inhibitor, 17-DMAG, Alone and in Combination with Lapatinib Attenuates Acquired Lapatinib-Resistance in ER-positive, HER2-Overexpressing Breast Cancer Cell Line. Cancers, 2020, 12, 2630.	1.7	9
50	Management of ER positive metastatic breast cancer. Seminars in Oncology, 2020, 47, 270-277.	0.8	25
51	Antibody Conjugation of Nanoparticles as Therapeutics for Breast Cancer Treatment. International Journal of Molecular Sciences, 2020, 21, 6018.	1.8	52
52	Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibodyâ€“Drug Conjugate. Molecular Cancer Therapeutics, 2020, 19, 2117-2125.	1.9	30
53	Evolving standards of care and new challenges in the management of HER2â€positive breast cancer. Ca-A Cancer Journal for Clinicians, 2020, 70, 355-374.	157.7	77
54	Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinib. Breast Cancer Research and Treatment, 2020, 184, 743-753.	1.1	4
55	Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial. Clinical Cancer Research, 2020, 26, 5820-5829.	3.2	68

#	Article	IF	Citations
56	Targeting molecular subtypes in solid cancers: successes and failures. Current Opinion in Oncology, 2020, 32, 488-493.	1.1	2
57	Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Current Treatment Standards and Future Perspectives. Breast Care, 2020, 15, 570-578.	0.8	7
58	Hepatic Metastasis from Breast Cancer. Seminars in Interventional Radiology, 2020, 37, 518-526.	0.3	6
59	Advancing Therapies for Cancerâ€"From Mustard Gas to CAR T. Sci, 2020, 2, 90.	1.8	0
60	Dose-reduced trastuzumab deruxtecan can be safely used in liver failure and active leptomeningeal metastases. Current Problems in Cancer Case Reports, 2020, 2, 100034.	0.1	1
61	Design, Synthesis, and Structureâ€"Activity Relationships of Novel Tetrahydroisoquinolino Benzodiazepine Dimer Antitumor Agents and Their Application in Antibodyâ€"Drug Conjugates. Journal of Medicinal Chemistry, 2020, 63, 13913-13950.	2.9	7
62	Treatment Landscape for Patients with HER2-Positive Metastatic Breast Cancer: A Review on Emerging Treatment Options . Cancer Management and Research, 2020, Volume 12, 10615-10629.	0.9	11
63	Advancing Therapies for Cancerâ€"From Mustard Gas to CAR T. Sci, 2020, 2, 70.	1.8	1
64	Trastuzumab Beyond Progression in Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: UK Practice now and in the Future. Clinical Oncology, 2020, 32, 636-638.	0.6	1
65	Whatâ€™s the Price? Toxicities of Targeted Therapies in Breast Cancer Care. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, 55-70.	1.8	13
66	On the use of DNA as a linker in antibody-drug conjugates: synthesis, stability and in vitro potency. Scientific Reports, 2020, 10, 7691.	1.6	20
67	HER2 antibody-drug conjugate controls growth of breast cancer brain metastases in hematogenous xenograft models, with heterogeneous bloodâ€"tumor barrier penetration unlinked to a passive marker. Neuro-Oncology, 2020, 22, 1625-1636.	0.6	23
68	The role of chemotherapy in treatment of advanced breast cancer: an overview for clinical practice. Critical Reviews in Oncology/Hematology, 2020, 153, 102988.	2.0	25
69	Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. New England Journal of Medicine, 2020, 382, 2419-2430.	13.9	681
70	Neratinib for the treatment of early-stage, hormone receptor-positive, HER2-overexpressed breast cancer. Future Oncology, 2020, 16, 1165-1177.	1.1	2
71	T-DM1-induced thrombocytopenia in breast cancer patients: New perspectives. Biomedicine and Pharmacotherapy, 2020, 129, 110407.	2.5	12
72	Antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapy. Expert Opinion on Biological Therapy, 2021, 21, 931-943.	1.4	49
73	New Therapeutics in HER2-Positive Advanced Breast Cancer: Towards a Change in Clinical Practices?. Cancers, 2020, 12, 1573.	1.7	25

#	Article	IF	Citations
74	The emerging role of antibody-drug conjugates in urothelial carcinoma. Expert Review of Anticancer Therapy, 2020, 20, 551-561.	1.1	23
76	Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond. Npj Breast Cancer, 2020, 6, 10.	2.3	106
77	The Second Generation Antibody-Drug Conjugate SYD985 Overcomes Resistances to T-DM1. Cancers, 2020, 12, 670.	1.7	31
78	Trastuzumab Deruxtecan: First Approval. Drugs, 2020, 80, 501-508.	4.9	133
79	Challenges in the treatment of breast cancer brain metastases: evidence, unresolved questions, and a practical algorithm. Clinical and Translational Oncology, 2020, 22, 1698-1709.	1.2	9
80	Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments. Medical Sciences (Basel, Switzerland), 2020, 8, 18.	1.3	72
81	Crosstalk between HER2 and PD-1/PD-L1 in Breast Cancer: From Clinical Applications to Mathematical Models. Cancers, 2020, 12, 636.	1.7	40
82	Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer. Breast Cancer Research and Treatment, 2020, 183, 23-39.	1.1	52
83	Management of Breast Cancer During the COVID-19 Pandemic: A Stage- and Subtype-Specific Approach. JCO Oncology Practice, 2020, 16, 665-674.	1.4	44
84	Use of HER2-Directed Therapy in Metastatic Breast Cancer and How Community Physicians Collaborate to Improve Care. Journal of Clinical Medicine, 2020, 9, 1984.	1.0	5
85	Advancing Therapies for Cancerâ€"From Mustard Gas to CAR T. Sci, 2020, 2, 42.	1.8	2
86	Circulating Tumor DNA Biomarkers for Early Detection of Oligometastasis. Cancer Journal (Sudbury,) Tj ETQq1 1 0.784314 rgBT /Over	1.0	15
87	Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors. Cancer Treatment Reviews, 2020, 88, 102064.	3.4	41
88	Antibody-Drug Conjugates and Targeted Treatment Strategies for Hepatocellular Carcinoma: A Drug-Delivery Perspective. Molecules, 2020, 25, 2861.	1.7	14
89	Antibodyâ€"drug conjugates for the treatment of urothelial carcinoma. Expert Opinion on Biological Therapy, 2021, 21, 915-922.	1.4	4
90	Anti-HER2 therapy for breast cancer in older patients. Future Oncology, 2020, 16, 1393-1407.	1.1	0
91	B-cell epitope peptide cancer vaccines: a new paradigm for combination immunotherapies with novel checkpoint peptide vaccine. Future Oncology, 2020, 16, 1767-1791.	1.1	16
92	Landscape of combination therapy trials in breast cancer brain metastasis. International Journal of Cancer, 2020, 147, 1939-1952.	2.3	31

#	Article	IF	Citations
93	Human Epidermal Growth Factor Receptor 2 (HER2) in Advanced Gastric Cancer: Current Knowledge and Future Perspectives. Drugs, 2020, 80, 401-415.	4.9	42
94	Neratinib: the emergence of a new player in the management of HER2+ breast cancer brain metastasis. Future Oncology, 2020, 16, 247-254.	1.1	15
95	Treatment from within: Ductal Carcinoma as an Opportunity to Harness the Immune System. Current Breast Cancer Reports, 2020, 12, 82-89.	0.5	0
96	Major Strides in HER2 Blockade for Metastatic Breast Cancer. New England Journal of Medicine, 2020, 382, 669-671.	13.9	6
97	Emerging Targeted Therapies for HER2 Positive Gastric Cancer That Can Overcome Trastuzumab Resistance. Cancers, 2020, 12, 400.	1.7	50
98	Perspectives on geriatric oncology research presented at the 2019 San Antonio Breast Cancer Symposium. Journal of Geriatric Oncology, 2020, 11, 740-744.	0.5	0
99	2019 San Antonio Breast Cancer Symposium: San Antonio, TX, USA, 10â€“14 December 2019. Targeted Oncology, 2020, 15, 7-9.	1.7	0
100	Cryptophycin-55/52 based antibody-drug conjugates: Synthesis, efficacy, and mode of action studies. European Journal of Medicinal Chemistry, 2020, 199, 112364.	2.6	15
103	Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance. Cancer Cell, 2020, 37, 471-484.	7.7	485
104	Biologic therapy for advanced breast cancer: recent advances and future directions. Expert Opinion on Biological Therapy, 2020, 20, 1009-1024.	1.4	23
105	HER3 targeting with an antibodyâ€drug conjugate bypasses resistance to antiâ€HER2 therapies. EMBO Molecular Medicine, 2020, 12, e11498.	3.3	30
106	Modeling biological and genetic diversity in upper tract urothelial carcinoma with patient derived xenografts. Nature Communications, 2020, 11, 1975.	5.8	37
107	Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial. Lancet Oncology, The, 2020, 21, 763-775.	5.1	144
108	Update Breast Cancer 2020 Part 2 â€“ Advanced Breast Cancer: New Treatments and Implementation of Therapies with Companion Diagnostics. Geburtshilfe Und Frauenheilkunde, 2020, 80, 391-398.	0.8	12
109	Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy. Expert Opinion on Biological Therapy, 2020, 20, 871-885.	1.4	57
110	Highlights from the San Antonio Breast Cancer Symposium (SABCS) 2019. Breast Care, 2020, 15, 192-196.	0.8	0
111	The Resurgence of Antibody Drug Conjugates in Cancer Therapeutics: Novel Targets and Payloads. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e58-e74.	1.8	36
112	Best Foot Forward: Neoadjuvant Systemic Therapy as Standard of Care in Triple-Negative and HER2-Positive Breast Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e1-e16.	1.8	9

#	Article	IF	Citations
113	Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors. Cancer Discovery, 2020, 10, 688-701.	7.7	212
114	HER2-Mediated Internalization of Cytotoxic Agents inERBB2Amplified or Mutant Lung Cancers. Cancer Discovery, 2020, 10, 674-687.	7.7	149
115	Escalating and De-escalating Therapy for Early-Stage HER2-Positive Breast Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, 3-13.	1.8	8
116	Antibody-Drug Conjugates: Patient and Treatment Selection. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, 105-114.	1.8	12
117	The Evolution of Antibody-Drug Conjugates: A Positive Inflexion Point. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, 127-134.	1.8	24
118	Awake breast cancer surgery: strategy in the beginning of COVID-19 emergency. Breast Cancer, 2021, 28, 137-144.	1.3	24
119	Immuno-PET Detects Changes in Multi-RTK Tumor Cell Expression Levels in Response to Targeted Kinase Inhibition. Journal of Nuclear Medicine, 2021, 62, 366-371.	2.8	4
120	The root cause of drug resistance in HER2-positive breast cancer and the therapeutic approaches to overcoming the resistance. , 2021, 218, 107677.		31
121	Antiâ€EGFR antibodyâ€drug conjugate for tripleâ€negative breast cancer therapy. Engineering in Life Sciences, 2021, 21, 37-44.	2.0	20
122	FDA Approval Summary: Tucatinib for the Treatment of Patients with Advanced or Metastatic HER2-positive Breast Cancer. Clinical Cancer Research, 2021, 27, 1220-1226.	3.2	36
123	FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer. Clinical Cancer Research, 2021, 27, 1850-1854.	3.2	57
124	Antibody Co-Administration Can Improve Systemic and Local Distribution of Antibodyâ€“Drug Conjugates to IncreaseIn VivoEfficacy. Molecular Cancer Therapeutics, 2021, 20, 203-212.	1.9	19
125	HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1371-1389.	3.3	63
126	Margetuximab for the treatment of HER2-positive metastatic breast cancer. Expert Opinion on Biological Therapy, 2021, 21, 127-133.	1.4	21
127	Trastuzumab emtansine (T-DM1) as adjuvant treatment of HER2-positive early breast cancer: safety and efficacy. Expert Review of Anticancer Therapy, 2021, 21, 241-250.	1.1	6
128	Management of Chemotherapy-Induced Nausea and Vomiting with Trastuzumab Deruxtecan: A Case Series. Breast Care, 2021, 16, 408-411.	0.8	6
129	Cost-effectiveness of treatments for HER2-positive metastatic breast cancer and associated metastases: an overview of systematic reviews. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 353-364.	0.7	5
130	Brain metastases in metastatic cancer: a review of recent advances in systemic therapies. Expert Review of Anticancer Therapy, 2021, 21, 325-339.	1.1	10

#	Article	IF	Citations
131	Brain metastasis models: What should we aim to achieve better treatments?. Advanced Drug Delivery Reviews, 2021, 169, 79-99.	6.6	13
132	Concurrent Radiation and Modern Systemic Therapies for Breast Cancer: An Ever-Expanding Frontier. Clinical Breast Cancer, 2021, 21, 120-127.	1.1	2
133	Neratinib Plus Capecibine in Patients With HER2-Positive Metastatic Breast Cancer. Journal of Clinical Oncology, 2021, 39, 252-253.	0.8	1
134	Perdurable PD-1 blockage awakes anti-tumor immunity suppressed by precise chemotherapy. Journal of Controlled Release, 2021, 329, 1023-1036.	4.8	18
135	Population Pharmacokinetics of Trastuzumab Deruxtecan in Patients With HER2â€Positive Breast Cancer and Other Solid Tumors. Clinical Pharmacology and Therapeutics, 2021, 109, 1314-1325.	2.3	25
136	Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptorâ˜positive Metastatic Breast Cancer or Other Solid Tumors. Clinical Cancer Research, 2021, 27, 1247-1255.	3.2	5
137	Development and biological assessment of MMAE-trastuzumab antibodyâ€“drug conjugates (ADCs). Breast Cancer, 2021, 28, 216-225.	1.3	10
138	Research advances and new challenges in overcoming triple-negative breast cancer. , 2021, 4, 517-542.		11
139	Targeting HER2 in Biliary Tract Carcinomas: Challenges and Opportunities. Oncology Research and Treatment, 2021, 44, 1-3.	0.8	10
140	Prolonged Survival in Patients with Human Epidermal Growth Factor Receptor-2-Overexpressed Metastatic Breast Cancer after Targeted Therapy is Dominantly Contributed by Luminal-Human Epidermal Growth Factor Receptor-2 Population. Oncologie, 2021, 23, 229-239.	0.2	1
141	Cancer Vaccines, Treatment of the Future: With Emphasis on HER2-Positive Breast Cancer. International Journal of Molecular Sciences, 2021, 22, 779.	1.8	53
142	The Rise of the TROP2-Targeting Agents in NSCLC: New Options on the Horizon. Oncology, 2021, 99, 673-680.	0.9	6
144	Clinical benefit of treatment after trastuzumab emtansine for HER2-positive metastatic breast cancer: a real-world multi-centre cohort study in Japan (WJOG12519B). Breast Cancer, 2021, 28, 581-591.	1.3	7
145	Challenges and Considerations on Risk-Reducing Surgery in BRCA1/2 Patients with Advanced Breast Cancer. Current Oncology, 2021, 28, 485-490.	0.9	1
146	N-terminal selective conjugation method widens the therapeutic window of antibodyâ€“drug conjugates by improving tolerability and stability. MAbs, 2021, 13, 1914885.	2.6	3
147	The evolution and advances of biomarker use in clinical trials for breast cancer treatmentâ€”a narrative review. Translational Breast Cancer Research, 0, 2, 6-6.	0.4	0
148	Discovery research and translation science of trastuzumab deruxtecan, from non-clinical study to clinical trial. Translational and Regulatory Sciences, 2021, 3, 65-71.	0.2	0
149	Leucine-rich alpha-2-glycoprotein 1 (LRG1) as a novel ADC target. RSC Chemical Biology, 2021, 2, 1206-1220.	2.0	15

#	Article	IF	Citations
150	Salting the Soil: Targeting the Microenvironment of Brain Metastases. Molecular Cancer Therapeutics, 2021, 20, 455-466.	1.9	13
151	Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592098651.	1.4	16
152	Recent advances in the treatment of hormone receptor-positive/human epidermal growth factor 2-positive advanced breast cancer. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110133.	1.4	9
153	Quantitative Determination of Intracellular Bond Cleavage. Methods in Pharmacology and Toxicology, 2021, , 305-330.	0.1	1
154	Identification of Prostaglandin F2 Receptor Negative Regulator (PTGFRN) as an internalizable target in cancer cells for antibody-drug conjugate development. PLoS ONE, 2021, 16, e0246197.	1.1	5
155	Antibodyâ€“drug conjugates in solid tumors: a look into novel targets. Journal of Hematology and Oncology, 2021, 14, 20.	6.9	129
156	The Development of Antibody-Drug Conjugates for Urothelial Carcinoma Treatment. The Korean Journal of Urological Oncology, 2021, 19, 30-39.	0.1	0
157	Disseminated cancer cells in breast cancer: Mechanism of dissemination and dormancy and emerging insights on therapeutic opportunities. Seminars in Cancer Biology, 2022, 78, 78-89.	4.3	16
158	Frontiers in HER2-positive breast cancer in 2020. Current Opinion in Obstetrics and Gynecology, 2021, 33, 48-52.	0.9	1
159	A Decade of FDA-Approved Drugs (2010â€“2019): Trends and Future Directions. Journal of Medicinal Chemistry, 2021, 64, 2312-2338.	2.9	145
160	The changing treatment of metastatic her2â€‘positive breast cancer (Review). Oncology Letters, 2021, 21, 287.	0.8	5
161	Tumour-Agnostic Therapy for Pancreatic Cancer and Biliary Tract Cancer. Diagnostics, 2021, 11, 252.	1.3	2
162	A Review of Fam-Trastuzumab Deruxtecan-nxki in HER2-Positive Breast Cancer. Annals of Pharmacotherapy, 2021, 55, 1410-1418.	0.9	13
163	Activity of novel anti-HER2 agents for breast cancer based on hormone receptors expression. Breast Cancer Research and Treatment, 2021, 186, 885-886.	1.1	3
164	Extracellular vesicles as modifiers of antibodyâ€drug conjugate efficacy. Journal of Extracellular Vesicles, 2021, 10, e12070.	5.5	17
165	Unlocking the potential of antibodyâ€“drug conjugates for cancer therapy. Nature Reviews Clinical Oncology, 2021, 18, 327-344.	12.5	498
166	Profile of Trastuzumab Deruxtecan in the Management of Patients with HER2-Positive Unresectable or Metastatic Breast Cancer: An Evidence-Based Review. Breast Cancer: Targets and Therapy, 2021, Volume 13, 151-159.	1.0	10
167	Improving Antibodyâ€Tubulysin Conjugates through Linker Chemistry and Siteâ€Specific Conjugation. ChemMedChem, 2021, 16, 1077-1081.	1.6	7

#	Article	IF	Citations
168	The Advances and Challenges of NK Cell-Based Cancer Immunotherapy. Current Oncology, 2021, 28, 1077-1093.	0.9	24
169	Optimal Strategies for Successful Initiation of Neratinib in Patients with HER2-Positive Breast Cancer. Clinical Breast Cancer, 2021, 21, e575-e583.	1.1	7
170	Identification and Therapeutic Targeting of GPR20, Selectively Expressed in Gastrointestinal Stromal Tumors, with DS-6157a, a First-in-Class Antibodyâ€“Drug Conjugate. Cancer Discovery, 2021, 11, 1508-1523.	7.7	20
171	Novel Anti-FOLR1 Antibodyâ€“Drug Conjugate MORAb-202 in Breast Cancer and Non-Small Cell Lung Cancer Cells. Antibodies, 2021, 10, 6.	1.2	10
172	Dual- versus single-agent HER2 inhibition and incidence of intracranial metastatic disease: a systematic review and meta-analysis. Npj Breast Cancer, 2021, 7, 17.	2.3	2
173	What makes a good antibodyâ€“drug conjugate?. Expert Opinion on Biological Therapy, 2021, 21, 841-847.	1.4	22
174	Clinical Development of New Antibodyâ€“Drug Conjugates in Breast Cancer: To Infinity and Beyond. BioDrugs, 2021, 35, 159-174.	2.2	30
175	Development of the CKâ€MBâ€1 trastuzumabâ€resistant HER2â€positive breast cancer cell line and xenograft animal models. Cancer Medicine, 2021, 10, 2370-2379.	1.3	0
177	The Exciting New Field of HER2-Low Breast Cancer Treatment. Cancers, 2021, 13, 1015.	1.7	83
178	Overview of recent advances in metastatic triple negative breast cancer. World Journal of Clinical Oncology, 2021, 12, 164-182.	0.9	42
179	Targeting HER2 in breast cancer: new drugs and paradigms on the horizon. Exploration of Targeted Anti-tumor Therapy, 0, , .	0.5	1
180	Brazilian Group of Gastrointestinal Tumoursâ€™ consensus guidelines for the management of oesophageal cancer. Ecancermedicalscience, 2021, 15, 1195.	0.6	1
181	Personalized therapeutic strategies in HER2-driven gastric cancer. Gastric Cancer, 2021, 24, 897-912.	2.7	6
182	The evolving paradigm of biomarker actionability: Histology-agnosticism as a spectrum, rather than a binary quality. Cancer Treatment Reviews, 2021, 94, 102169.	3.4	14
183	HER2-/HER3-Targeting Antibodyâ€”Drug Conjugates for Treating Lung and Colorectal Cancers Resistant to EGFR Inhibitors. Cancers, 2021, 13, 1047.	1.7	27
184	Trastuzumab deruxtecan for the treatment of HER2-positive advanced gastric cancer: a clinical perspective. Gastric Cancer, 2021, 24, 567-576.	2.7	19
185	Immunotherapy as a partner for HER2-directed therapies. Expert Review of Anticancer Therapy, 2021, 21, 739-746.	1.1	5
186	Signaling Pathways in Cancer: Therapeutic Targets, Combinatorial Treatments, and New Developments. Cells, 2021, 10, 659.	1.8	77

#	Article	IF	Citations
187	Synthetic Approaches to the New Drugs Approved during 2019. Journal of Medicinal Chemistry, 2021, 64, 3604-3657.	2.9	30
188	Drug-Related Pneumonitis in Cancer Treatment during the COVID-19 Era. Cancers, 2021, 13, 1052.	1.7	5
189	FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast Cancer. Clinical Cancer Research, 2021, 27, 4478-4485.	3.2	67
190	TAM-ing the CIAâ€"Tumor-Associated Macrophages and Their Potential Role in Unintended Side Effects of Therapeutics for Cancer-Induced Anemia. Frontiers in Oncology, 2021, 11, 627223.	1.3	3
191	Emerging Therapeutics for Patients with Triple-Negative Breast Cancer. Current Oncology Reports, 2021, 23, 57.	1.8	30
192	6 versus 12â€Šmonths of adjuvant trastuzumab in HER2+ early breast cancer. Medicine (United States), 2021, 100, e24995.	0.4	2
193	Breast Cancer Brain Metastasisâ€"Overview of Disease State, Treatment Options and Future Perspectives. Cancers, 2021, 13, 1078.	1.7	41
194	Early, On-Treatment Levels and Dynamic Changes of Genomic Instability in Circulating Tumor DNA Predict Response to Treatment and Outcome in Metastatic Breast Cancer Patients. Cancers, 2021, 13, 1331.	1.7	7
195	Cardiovascular toxicity of breast cancer treatment: an update. Cancer Chemotherapy and Pharmacology, 2021, 88, 15-24.	1.1	7
196	Tucatinib approval by EMA expands options for HER2-positive locally advanced or metastatic breast cancer. ESMO Open, 2021, 6, 100063.	2.0	7
197	Revisiting antibody-drug conjugates and their predictive biomarkers in platinum-resistant ovarian cancer. Seminars in Cancer Biology, 2021, 77, 42-55.	4.3	10
199	Trastuzumab deruxtecan for the treatment of HER2-positive gastric cancer. Expert Opinion on Biological Therapy, 2021, 21, 825-830.	1.4	6
200	The Promising Evolution of Targeted Therapeutic Strategies in Cancer. Cancer Discovery, 2021, 11, 810-814.	7.7	10
201	Neratinibâ€‰+â€‰capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer andâ€‰â‰¥â€‰2 prior HER2-directed regimens. Breast Cancer Research and Treatment, 2021, 188, 449-458.	3.1	2
202	Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond. Expert Opinion on Biological Therapy, 2021, 21, 811-824.	1.4	16
203	T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study. ESMO Open, 2021, 6, 100099.	2.0	12
204	Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response. Nature Cancer, 2021, 2, 400-413.	5.7	41
205	Update Breast Cancer 2020 Part 5 â€“ Moving Therapies From Advanced to Early Breast Cancer Patients. Geburtshilfe Und Frauenheilkunde, 2021, 81, 469-480.	0.8	6

#	Article	IF	Citations
206	Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors. International Journal of Molecular Sciences, 2021, 22, 4774.	1.8	55
207	2019â€“2020 Drug Updates in Solid Tumors. Journal of the Advanced Practitioner in Oncology, 2021, 12, 275-278.	0.2	0
208	Th1 cytokine interferon gamma improves response in HER2 breast cancer by modulating the ubiquitin proteasomal pathway. Molecular Therapy, 2021, 29, 1541-1556.	3.7	20
209	Exploring the concepts and practices of advanced breast cancer treatment: a narrative review. Annals of Translational Medicine, 2021, 9, 721-721.	0.7	3
210	Clinical therapeutic effects of trastuzumab in HER2-positive breast cancer patients. Medicine (United) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.4	0
211	Mesoporous silica nanoparticle: Heralding a brighter future in cancer nanomedicine. Microporous and Mesoporous Materials, 2021, 319, 110967.	2.2	23
212	A nomogram for predicting brain metastasis in patients with de novo stage IV breast cancer. Annals of Translational Medicine, 2021, 9, 853-853.	0.7	4
213	First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibodyâ€“Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer. Molecular Cancer Therapeutics, 2021, 20, 1442-1453.	1.9	38
214	The Landscape of Antibody-drug Conjugates in Urothelial Cancer. Advances in Oncology, 2021, 1, 273-282.	0.1	0
215	Breast cancer. Lancet, The, 2021, 397, 1750-1769.	6.3	731
216	Current State of Breast Cancer Diagnosis, Treatment, and Theranostics. Pharmaceutics, 2021, 13, 723.	2.0	63
217	Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer. Gastric Cancer, 2021, 24, 780-789.	2.7	24
218	Visualization of Intratumor Pharmacokinetics of [fam-] Trastuzumab Deruxtecan (DS-8201a) in HER2 Heterogeneous Model Using Phosphor-integrated Dots Imaging Analysis. Clinical Cancer Research, 2021, 27, 3970-3979.	3.2	15
219	The Expanding Role of Chemistry in Optimizing Proteins for Human Health Applications. Journal of Medicinal Chemistry, 2021, 64, 7179-7188.	2.9	8
220	HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now. Npj Breast Cancer, 2021, 7, 56.	2.3	123
221	The Immunotherapy Landscape in Adrenocortical Cancer. Cancers, 2021, 13, 2660.	1.7	8
222	Treating Advanced Unresectable or Metastatic HER2-Positive Breast Cancer: A Spotlight on Tucatinib. Breast Cancer: Targets and Therapy, 2021, Volume 13, 361-381.	1.0	8
223	Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Lancet Oncology, The, 2021, 22, 779-789.	5.1	234

#	Article	IF	Citations
224	Treating Bladder Cancer: Engineering of Current and Next Generation Antibody-, Fusion Protein-, mRNA-, Cell- and Viral-Based Therapeutics. Frontiers in Oncology, 2021, 11, 672262.	1.3	11
225	Brain metastases: new systemic treatment approaches. Memo - Magazine of European Medical Oncology, 2021, 14, 198-203.	0.3	3
226	Kinase drug discovery 20 years after imatinib: progress and future directions. Nature Reviews Drug Discovery, 2021, 20, 551-569.	21.5	497
227	Antibodyâ€“Drug Conjugates for the Treatment of Breast Cancer. Cancers, 2021, 13, 2898.	1.7	34
228	Current and Future Management of HER2-Positive Metastatic Breast Cancer. JCO Oncology Practice, 2021, 17, 594-604.	1.4	102
229	Expression pattern and prognostic impact of glycoprotein non-metastatic B (GPNMB) in triple-negative breast cancer. Scientific Reports, 2021, 11, 12171.	1.6	15
230	Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies. Breast Cancer Research and Treatment, 2021, 188, 21-36.	1.1	62
231	Exposureâ€Response Relationships in Patients With HER2â€Positive Metastatic Breast Cancer and Other Solid Tumors Treated With Trastuzumab Deruxtecan. Clinical Pharmacology and Therapeutics, 2021, 110, 986-996.	2.3	20
232	The Clinical Efficacy and Safety of Neratinib in Combination with Capecitabine for the Treatment of Adult Patients with Advanced or Metastatic HER2-Positive Breast Cancer. Drug Design, Development and Therapy, 2021, Volume 15, 2711-2720.	2.0	11
233	Targeting mTOR and Glycolysis in HER2-Positive Breast Cancer. Cancers, 2021, 13, 2922.	1.7	29
234	The promising role of antibody drug conjugate in cancer therapy: Combining targeting ability with cytotoxicity effectively. Cancer Medicine, 2021, 10, 4677-4696.	1.3	25
235	Brain Metastases in HER2-Positive Breast Cancer: Current and Novel Treatment Strategies. Cancers, 2021, 13, 2927.	1.7	54
236	New Therapeutic Strategies in Advanced Nonoperable or Metastatic HER2-positive Breast Cancer. Geburtshilfe Und Frauenheilkunde, 2021, 81, 666-678.	0.8	1
237	Precision Medicine in Oncology: A Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer. Journal of Personalized Medicine, 2021, 11, 518.	1.1	8
238	Targeting HER2 genomic alterations in non-small cell lung cancer. Journal of the National Cancer Center, 2021, 1, 58-73.	3.0	13
239	Therapeutic Potential of Antibody-Drug Conjugate-Based Therapy in Head and Neck Cancer: A Systematic Review. Cancers, 2021, 13, 3126.	1.7	12
240	Role of receptor tyrosine kinases mediated signal transduction pathways in tumor growth and angiogenesisâ€”New insight and futuristic vision. International Journal of Biological Macromolecules, 2021, 180, 739-752.	3.6	39
241	New safer management for breast cancer patients who need neoadjuvant therapy during SARS-COVID pandemic. Breast Disease, 2021, 41, 1-3.	0.4	0

#	Article	IF	Citations
242	Mastering the Use of Novel Anti-HER2 Treatment Options. JCO Oncology Practice, 2021, 17, 605-606.	1.4	6
243	Identification of cell surface targets for CAR-T cell therapies and antibodyâ€“drug conjugates in breast cancer. ESMO Open, 2021, 6, 100102.	2.0	24
244	Investigational antibody-drug conjugates in clinical trials for the treatment of breast cancer. Expert Opinion on Investigational Drugs, 2021, 30, 1-7.	1.9	3
245	Progress in Gynecologic Cancers with Antibody Drug Conjugates. Current Oncology Reports, 2021, 23, 89.	1.8	3
246	Developing Precision Medicine for Bladder Cancer. Hematology/Oncology Clinics of North America, 2021, 35, 633-653.	0.9	9
247	Management of Early-Stage Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer. JCO Oncology Practice, 2021, 17, 320-330.	1.4	14
249	SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer. Memo - Magazine of European Medical Oncology, 2021, 14, 247-251.	0.3	9
250	Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics. Expert Opinion on Biological Therapy, 2021, 21, 945-962.	1.4	26
251	Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer. Breast Cancer Research and Treatment, 2021, 189, 177-185.	1.1	15
252	Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities. Oncologist, 2021, 26, 827-834.	1.9	28
253	A Review of Treatment-Induced Pulmonary Toxicity in Breast Cancer. Clinical Breast Cancer, 2022, 22, 1-9.	1.1	6
254	Impact of Endocytosis Mechanisms for the Receptors Targeted by the Currently Approved Antibody-Drug Conjugates (ADCs)â€”A Necessity for Future ADC Research and Development. Pharmaceuticals, 2021, 14, 674.	1.7	26
255	Understanding and overcoming tumor heterogeneity in metastatic breast cancer treatment. Nature Cancer, 2021, 2, 680-692.	5.7	56
256	Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapies in HER2-positive breast cancer. Cancer Letters, 2021, 511, 77-87.	3.2	22
257	Effect of the 2013 ASCO-CAP HER2 Testing Guideline on the Management of IHC/HER2 2+ Invasive Breast Cancer. Anticancer Research, 2021, 41, 4143-4149.	0.5	1
258	Modelâ€Informed Therapeutic Dose Optimization Strategies for Antibodyâ€“Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administrationâ€“Approved Antibodyâ€“Drug Conjugates?. Clinical Pharmacology and Therapeutics, 2021, 110, 1216-1230.	2.3	25
259	Prolonged Survival in Patients with Metastatic HER2-Positive Inflammatory Breast Cancer: A Case Report and Review of the Literature. Case Reports in Oncology, 2021, 14, 1071-1079.	0.3	5
260	Highlights of the San Antonio Breast Cancer Symposium 2020: part 2. Future Oncology, 2021, 17, 2699-2703.	1.1	0

#	Article	IF	Citations
261	Antibody Drug Conjugates in Lung Cancer: State of the Current Therapeutic Landscape and Future Developments. Clinical Lung Cancer, 2021, 22, 483-499.	1.1	11
262	A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast cancer. Breast Cancer Research and Treatment, 2021, 189, 411-423.	1.1	3
263	Exploiting somatic alterations as therapeutic targets in advanced and metastatic cervical cancer. Cancer Treatment Reviews, 2021, 98, 102225.	3.4	11
264	Central neurotoxicity induced by trastuzumab emtansine (T-DM1). Anti-Cancer Drugs, 2021, Publish Ahead of Print, 1146-1149.	0.7	5
265	Importance and Considerations of Antibody Engineering in Antibody-Drug Conjugates Development from a Clinical Pharmacologistâ€™s Perspective. Antibodies, 2021, 10, 30.	1.2	13
266	Optimal Management for Residual Disease Following Neoadjuvant Systemic Therapy. Current Treatment Options in Oncology, 2021, 22, 79.	1.3	13
267	Functional genomics for breast cancer drug target discovery. Journal of Human Genetics, 2021, 66, 927-935.	1.1	9
268	Landmark trials in the medical oncology management of metastatic breast cancer. Seminars in Oncology, 2021, 48, 246-258.	0.8	4
269	Preclinical evaluation of MRG002, a novel HER2-targeting antibody-drug conjugate with potent antitumor activity against HER2-positive solid tumors. Antibody Therapeutics, 2021, 4, 175-184.	1.2	14
270	Pharmacogenomicâ€Guided Therapy in Colorectal Cancer. Clinical Pharmacology and Therapeutics, 2021, 110, 616-625.	2.3	14
271	Real-world effectiveness of post-trastuzumab emtansine treatment in patients with HER2-positive, unresectable and/or metastatic breast cancer: a retrospective observational study (KBCSG-TR 1917). BMC Cancer, 2021, 21, 795.	1.1	3
272	Evaluation of overall survival and barriers to surgery for patients with breast cancer treated without surgery: a National Cancer Database analysis. Npj Breast Cancer, 2021, 7, 87.	2.3	7
273	Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine in Patients With Previously Treated HER2-Positive Metastatic Breast Cancer: A Multicenter, Retrospective Study. Frontiers in Oncology, 2021, 11, 699333.	1.3	5
274	DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo. Gynecologic Oncology, 2021, 163, 334-341.	0.6	10
275	First advanced course on biomarkers in molecular and immuno-oncology in the Middle East. Future Oncology, 2021, 17, 2831-2834.	1.1	0
276	Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions. Breast Cancer Research, 2021, 23, 84.	2.2	108
277	Sacituzumab govitecan and trastuzumab deruxtecan: two new antibodyâ€“drug conjugates in the breast cancer treatment landscape. ESMO Open, 2021, 6, 100204.	2.0	30
278	Datopotamab Deruxtecan, a Novel TROP2-directed Antibodyâ€“drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells. Molecular Cancer Therapeutics, 2021, 20, 2329-2340.	1.9	85

#	Article	IF	Citations
279	Efficacy and Safety of Anti-HER2 Agents in Combination With Chemotherapy for Metastatic HER2-Positive Breast Cancer Patient: A Network Meta-Analysis. Frontiers in Oncology, 2021, 11, 731210.	1.3	5
280	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer. , 2021, 9, e002597.		45
281	Breast Cancer Treatments: Updates and New Challenges. Journal of Personalized Medicine, 2021, 11, 808.	1.1	108
282	Is Molecular Tailored-Therapy Changing the Paradigm for CNS Metastases in Breast Cancer?. Clinical Drug Investigation, 2021, 41, 757-773.	1.1	1
283	Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncology, The, 2021, 22, 1151-1161.	5.1	248
284	Long-Term Outcomes of a Randomized Study of Neoadjuvant Induction Dual HER2 Blockade with Trastuzumab and Lapatinib Followed by Weekly Paclitaxel Plus Dual HER2 Blockade for HER2-Positive Primary Breast Cancer (Neo-Lath Study). Cancers, 2021, 13, 4008.	1.7	3
285	Efficacy of tucatinib for HER2-positive metastatic breast cancer after HER2-targeted therapy: a network meta-analysis. Future Oncology, 2021, 17, 4635-4647.	1.1	6
286	Current status and future perspectives of onco-cardiology: Importance of early detection and intervention for cardiotoxicity, and cardiovascular complication of novel cancer treatment. Global Health & Medicine, 2021, 3, 214-225.	0.6	9
287	An Anti-HER2 Monoclonal Antibody H₂Mab-41 Exerts Antitumor Activities in Mouse Xenograft Model Using Dog HER2-Overexpressed Cells. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2021, 40, 184-190.	0.8	10
288	Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer. Current Oncology Reports, 2021, 23, 128.	1.8	18
289	Targeted Agents for HER2-Positive Breast Cancer: Optimal Use in Older Patients. Drugs and Aging, 2021, 38, 829-844.	1.3	0
290	Interconversion of Unexpected Thiol States Affects the Stability, Structure, and Dynamics of Antibody Engineered for Site-Specific Conjugation. Bioconjugate Chemistry, 2021, 32, 1834-1844.	1.8	3
291	The effects of T-DXd on the expression of HLA class I and chemokines CXCL9/10/11 in HER2-overexpressing gastric cancer cells. Scientific Reports, 2021, 11, 16891.	1.6	8
292	Targeted Therapies for Breast Cancer Brain Metastases. Clinical Breast Cancer, 2021, 21, 263-270.	1.1	3
293	Open questions and controversies in the systemic treatment of breast cancer. Current Opinion in Oncology, 2021, Publish Ahead of Print, 591-596.	1.1	1
294	Prognostic factors of brain metastasis and survival among HER2-positive metastatic breast ï»¿cancer patients: a systematic literature review. BMC Cancer, 2021, 21, 967.	1.1	22
295	Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer. Npj Breast Cancer, 2021, 7, 103.	2.3	17
296	Caution the arrhythmia association with antibody-drug conjugates: a pharmacovigilance study. Anti-Cancer Drugs, 2022, 33, e228-e234.	0.7	3

#	Article	IF	Citations
297	Recombinant immunotoxins development for HER2-based targeted cancer therapies. Cancer Cell International, 2021, 21, 470.	1.8	16
299	Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status. European Journal of Cancer, 2021, 155, 1-12.	1.3	39
300	Poziotinib for Patients With HER2 Exon 20 Mutant Nonâ€“Small-Cell Lung Cancer: Results From a Phase II Trial. Journal of Clinical Oncology, 2022, 40, 702-709.	0.8	53
301	Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitorâ€“Resistant, EGFR-Mutated Nonâ€“Small Cell Lung Cancer. Cancer Discovery, 2022, 12, 74-89.	7.7	133
302	Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer. Breast Cancer: Targets and Therapy, 2021, Volume 13, 539-557.	1.0	4
303	Circulating and Intracellular miRNAs as Prognostic and Predictive Factors in HER2-Positive Early Breast Cancer Treated with Neoadjuvant Chemotherapy: A Review of the Literature. Cancers, 2021, 13, 4894.	1.7	6
304	Trastuzumab Deruxtecan in HER2-Mutant Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2022, 386, 241-251.	13.9	393
305	An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy. Molecules, 2021, 26, 5847.	1.7	158
306	Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens. Breast Cancer Research and Treatment, 2021, 189, 665-676.	1.1	15
307	Breast cancer treatment-related cardiovascular disturbances: advocacy for a watchful attitude in this never-ending story. Expert Opinion on Drug Safety, 2021, , 1-13.	1.0	0
309	Acute eosinophilic pneumonia: a fatal reaction to ado-trastuzumab. BMJ Case Reports, 2021, 14, e243881.	0.2	2
310	Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis. PLoS ONE, 2021, 16, e0257976.	1.1	10
311	Brain Metastasis Treatment: The Place of Tyrosine Kinase Inhibitors and How to Facilitate Their Diffusion across the Bloodâ€“Brain Barrier. Pharmaceutics, 2021, 13, 1446.	2.0	11
312	A common goal to CARE: Cancer Advocates, Researchers, and Clinicians Explore current treatments and clinical trials for breast cancer brain metastases. Npj Breast Cancer, 2021, 7, 121.	2.3	6
313	The management of HER2â€positive early breast cancer: Current and future therapies. Asia-Pacific Journal of Clinical Oncology, 2021, 17, 3-12.	0.7	7
314	Extending traditional antibody therapies: Novel discoveries in immunotherapy and clinical applications. Molecular Therapy - Oncolytics, 2021, 22, 166-179.	2.0	17
317	Screening and Bioinformatics Analysis of Competitive Endogenous RNA Regulatory Network â€“â€“Related to Circular RNA in Breast Cancer. BioMed Research International, 2021, 2021, 1-13.	0.9	3
318	Heterogeneous HER2 Amplificationâ€”a New Clinical Category of HER2-Positive Breast Cancer?. Cancer Discovery, 2021, 11, 2369-2371.	7.7	5

#	Article	IF	Citations
319	Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Annals of Oncology, 2021, 32, 1216-1235.	0.6	354
320	Biosimilars in an era of rising oncology treatment options. Future Oncology, 2021, 17, 3881-3892.	1.1	5
321	Treatment and outcomes of older versus younger women with HER2-positive metastatic breast cancer in the real-world national ESME database. Breast, 2021, 60, 138-146.	0.9	5
322	Performance of enhancement on brain MRI for identifying HER2 overexpression in breast cancer brain metastases. European Journal of Radiology, 2021, 144, 109948.	1.2	6
323	Targeting HER2 heterogeneity in breast cancer. Cancer Treatment Reviews, 2021, 100, 102286.	3.4	46
324	Clinicopathologic features and treatment advances in cancers with HER2 alterations. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1876, 188605.	3.3	11
325	FGFR signaling and endocrine resistance in breast cancer: Challenges for the clinical development of FGFR inhibitors. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1876, 188595.	3.3	13
326	The effects of anticancer therapies on bone metastases in breast cancer. , 2022, , 987-1002.		0
328	AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2021. Breast Care, 2021, 16, 228-235.	0.8	20
329	Research Progress of Antibody-Drug Conjugate. Advances in Clinical Medicine, 2021, 11, 4135-4143.	0.0	2
330	Antitumour immunity regulated by aberrant ERBB family signalling. Nature Reviews Cancer, 2021, 21, 181-197.	12.8	141
331	Clinicopathological utility of human epidermal growth factor receptor 2 (HER2)-heterogeneity for next-generation treatments of triple-negative breast cancer. Oncotarget, 2021, 12, 2302-2304.	0.8	2
332	Immunoconjugates as immune canoes to kill breast cancer cells. , 2021, , 11-31.		1
333	Proteolysis targeting chimera technology: a novel strategy for treating diseases of the central nervous system. Neural Regeneration Research, 2021, 16, 1944.	1.6	8
335	Imaging of HER2-Positive Tumors in NOD/SCID Mice with Pertuzumab Fab-Hexahistidine Peptide Immunoconjugates Labeled with [99mTc]-(I)-Tricarbonyl Complex. Molecular Imaging and Biology, 2021, 23, 495-504.	1.3	2
336	Breast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches. Breast Cancer: Basic and Clinical Research, 2021, 15, 117822342199585.	0.6	22
337	Advances in EGFR/HER2-directed clinical research on breast cancer. Advances in Cancer Research, 2020, 147, 375-428.	1.9	8
338	HER2-positive advanced breast cancer treatment in 2020. Cancer Treatment Reviews, 2020, 88, 102033.	3.4	70

#	Article	IF	Citations
340	Targeting the Human Epidermal Growth Factor Receptor Family in Breast Cancer beyond HER2. Breast Care, 2020, 15, 579-585.	0.8	9
341	Emerging therapeutic agents for advanced non-small cell lung cancer. Journal of Hematology and Oncology, 2020, 13, 58.	6.9	161
342	HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates. Breast Cancer Research, 2020, 22, 15.	2.2	53
343	Genomic Alteration in Metastatic Breast Cancer and Its Treatment. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, 30-43.	1.8	107
344	Targeting HER2 expression in cancer: New drugs and new indications. Bosnian Journal of Basic Medical Sciences, 2021, 21, 1-4.	0.6	25
345	Second line trastuzumab emtansine following horizontal dual blockade in a real-life setting. Oncotarget, 2020, 11, 2083-2091.	0.8	7
346	NRXN1 as a novel potential target of antibody-drug conjugates for small cell lung cancer. Oncotarget, 2020, 11, 3590-3600.	0.8	8
347	HER2 splice variants in breast cancer: investigating their impact on diagnosis and treatment outcomes. Oncotarget, 2020, 11, 4338-4357.	0.8	22
348	Trastuzumab deruxtecan: A quantum leap in HER2-positive breast cancer. Indian Journal of Medical and Paediatric Oncology, 2019, 40, 556.	0.1	1
349	Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 452-478.	2.3	848
350	Recent developments in chemical conjugation strategies targeting native amino acids in proteins and their applications in antibodyâ€“drug conjugates. Chemical Science, 2021, 12, 13613-13647.	3.7	46
351	Antibody drug conjugates for patients with breast cancer. Current Problems in Cancer, 2021, 45, 100795.	1.0	3
352	SABR in oligometastatic breast cancer: Current status and future directions. Breast, 2021, 60, 223-229.	0.9	6
353	Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates. JAMA Oncology, 2021, 7, 1873.	3.4	66
354	Optimizing antiâ€“body drug conjugates and radiopharmaceuticals for precision therapy: The next frontier in precision oncology. Current Problems in Cancer, 2021, 45, 100799.	1.0	2
355	A Coalaâ€Tâ€Cannabis Survey Study of breast cancer patients' use of cannabis before, during, and after treatment. Cancer, 2022, 128, 160-168.	2.0	27
356	ASCO 2021â€”an update on metastastic colorectal cancer. Memo - Magazine of European Medical Oncology, 2021, 14, 319-322.	0.3	1
357	The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status. Breast Cancer, 2022, 29, 234-241.	1.3	90

#	Article	IF	Citations
358	Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer. Journal of Experimental and Clinical Cancer Research, 2021, 40, 313.	3.5	6
359	Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab. BMC Cancer, 2021, 21, 1150.	1.1	3
360	Gallbladder Cancer: Current Insights in Genetic Alterations and Their Possible Therapeutic Implications. Cancers, 2021, 13, 5257.	1.7	22
361	Central Nervous System Metastases. Hematology/Oncology Clinics of North America, 2022, 36, 161-188.	0.9	10
362	Clinical Review on the Management of Hormone Receptorâ€“Positive Metastatic Breast Cancer. JCO Oncology Practice, 2022, 18, 319-327.	1.4	40
363	Drug-induced pulmonary toxicity in breast cancer patients treated with systemic therapy: a systematic literature review. Expert Review of Anticancer Therapy, 2021, 21, 1399-1410.	1.1	0
364	Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer. Lung Cancer: Targets and Therapy, 2021, Volume 12, 103-114.	1.3	6
365	Case Report: Effective Treatment With Pyrotinib and Capecitabine in a Heavily Pretreated Locally Advanced Breast Cancer Harboring Both HER2 Overexpression and Mutant. Frontiers in Oncology, 2021, 11, 715554.	1.3	3
366	Breast Cancer Drug Approvals Issued by EMA: A Review of Clinical Trials. Cancers, 2021, 13, 5198.	1.7	10
367	Human epidermal growth factor receptor 2 targeted therapy in endometrial cancer: Clinical and pathological perspectives. World Journal of Clinical Oncology, 2021, 12, 868-881.	0.9	8
368	Antibody drug conjugates in gastrointestinal cancer: From lab to clinical development. Journal of Controlled Release, 2021, 340, 1-34.	4.8	11
369	Development ofHER2-targeted Therapies for Gastrointestinal Cancer. European Oncology and Haematology, 2020, 16, 29.	0.0	0
371	Novel antibodyâ€“drug conjugates: current and future roles in gynecologic oncology. Current Opinion in Obstetrics and Gynecology, 2021, 33, 26-33.	0.9	1
372	New Insights to Reshape the Management of Patients with Metastatic Breast Cancer - Focus on Overcoming Challenges in HER2 Status Interpretation. Open Biomarkers Journal, 2020, 10, 38-46.	0.1	0
373	Trastuzumab does not bind rat or mouse ErbB2/neu: implications for selection of non-clinical safety models for trastuzumab-based therapeutics. Breast Cancer Research and Treatment, 2022, 191, 303-317.	1.1	10
374	U.S. FDA Drug Approvals for Breast Cancer: A Decade in Review. Clinical Cancer Research, 2022, 28, 1072-1086.	3.2	31
375	Leptomeningeal Disease. Hematology/Oncology Clinics of North America, 2021, 36, 189-215.	0.9	1
376	Emerging combination immunotherapy strategies for breast cancer: dual immune checkpoint modulation, antibodyâ€“drug conjugates and bispecific antibodies. Breast Cancer Research and Treatment, 2022, 191, 291-302.	1.1	18

#	Article	IF	Citations
377	Adverse events of targeted therapies approved for women's cancers. International Journal of Women's Dermatology, 2021, 7, 552-559.	1.1	0
378	Cardiotoxicity of Epidermal Growth Factor Receptor 2-Targeted Drugs for Breast Cancer. Frontiers in Pharmacology, 2021, 12, 741451.	1.6	7
379	Characterization of Treatments and Disease Course for Women with Breast Cancer Brain Metastases: 5-Year Retrospective Single Institution Experience. Cancer Management and Research, 2021, Volume 13, 8191-8198.	0.9	5
380	Role of Her-2 in Gastrointestinal Tumours beyond Gastric Cancer: A Tool for Precision Medicine. Gastrointestinal Disorders, 2021, 3, 1-22.	0.4	7
381	HER2-targeted regimens after prior trastuzumab for patients with HER2-positive unresectable, locally advanced or metastatic breast cancer: a network meta-analysis of randomized controlled trials. Annals of Translational Medicine, 2020, 8, 1634-1634.	0.7	3
382	Microgravity: New aspect for breast cancer treatment, a review. Acta Astronautica, 2022, 190, 62-73.	1.7	5
383	Trastuzumab: A Milestone in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. Indian Journal of Medical and Paediatric Oncology, 2020, 41, 54-56.	0.1	0
385	Comparative effectiveness and tolerability of targeted agents combined with chemotherapy in patients with HER2-positive gastroesophageal cancer: A network meta-analysis. Saudi Journal of Gastroenterology, 2021, .	0.5	0
386	ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Annals of Oncology, 2021, 32, 1475-1495.	0.6	454
387	Advances with antibody-drug conjugates in breast cancer treatment. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 169, 241-255.	2.0	3
388	Focal radiotherapy of brain metastases in combination with immunotherapy and targeted drug therapy. Deutsches Ärzteblatt International, 2021, , .	0.6	4
389	HER2 targeting nearâ€infrared photoimmunotherapy for a CDDPâ€resistant smallâ€cell lung cancer. Cancer Medicine, 2021, 10, 8808-8819.	1.3	11
390	Practice-Changing Interventions in the Systemic Management of Breast Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 941-944.	2.3	0
392	Antibody-drug conjugates: an evolving approach for melanoma treatment. Melanoma Research, 2021, 31, 1-17.	0.6	4
393	Rate of reclassification of HER2-equivocal breast cancer cases to HER2-negative per the 2018 ASCO/CAP guidelines and response of HER2-equivocal cases to anti-HER2 therapy. PLoS ONE, 2020, 15, e0241775.	1.1	3
394	Treatment options for patients with brain metastatic disease in HER2-positive breast cancer. Indian Journal of Medical and Paediatric Oncology, 2020, 41, 735-737.	0.1	0
395	Antibody DDS therapeutics against cancer, inflammatory autoimmune and infectious disease. Drug Delivery System, 2020, 35, 356-366.	0.0	0
396	The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies. American Journal of Cancer Research, 2020, 10, 1045-1067.	1.4	25

#	Article	IF	Citations
397	Brazilian Group of Gastrointestinal Tumours' consensus guidelines for the management of gastric cancer. Ecancermedicalscience, 2020, 14, 1126.	0.6	3
398	Metabolic syndrome and breast cancer: a dangerous association for postmenopausal women. Acta Biomedica, 2021, 92, e2021177.	0.2	0
399	PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110598.	1.4	6
400	Mammakarzinom. , 2022, , 340-351.		0
401	How We Treat HER2-Positive Metastatic Breast Cancer. Indian Journal of Medical and Paediatric Oncology, 2021, 42, 370-375.	0.1	0
404	Antibodyâ€“drug conjugates: Smart chemotherapy delivery across tumor histologies. Ca-A Cancer Journal for Clinicians, 2022, 72, 165-182.	157.7	132
405	Drug-Induced Interstitial Lung Disease after Anthracycline-Combined Chemotherapy for Breast Cancer: A Case Report and Literature Review. Case Reports in Oncology, 2022, 14, 1671-1676.	0.3	4
406	Trastuzumab deruxtecan for HER2+ advanced breast cancer. Future Oncology, 2022, 18, 7-19.	1.1	18
407	The efficacy of lapatinib in patients with metastatic HER2 positive breast cancer who received prior therapy with monoclonal antibodies and antibody-drug conjugate: a single institutional experience. Journal of Chemotherapy, 2021, , 1-8.	0.7	0
408	Treatment landscape of triple-negative breast cancer â€” expanded options, evolving needs. Nature Reviews Clinical Oncology, 2022, 19, 91-113.	12.5	414
409	CDK4/6 inhibitors: A potential therapeutic approach for triple negative breast cancer. MedComm, 2021, 2, 514-530.	3.1	12
410	Precision medicine biomarkers in brain metastases: applications, discordances, and obstacles. Neuro-Oncology Advances, 2021, 3, v35-v42.	0.4	2
411	The tumor immune microenvironment of primary and metastatic HER2â˜ positive breast cancers utilizing gene expression and spatial proteomic profiling. Journal of Translational Medicine, 2021, 19, 480.	1.8	17
412	Advances in the management of breast cancer brain metastases. Neuro-Oncology Advances, 2021, 3, v63-v74.	0.4	10
413	Management of Diarrhea in Patients with HER2-Positive Breast Cancer Treated with Neratinib: A Case Series and Summary of the Literature. Oncology and Therapy, 2021, , 1.	1.0	4
414	A Retrospective Analysis of the Effect of Irinotecan-Based Regimens in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes. Frontiers in Oncology, 2021, 11, 654974.	1.3	3
415	Immunotherapy in Breast Cancer: When, How, and What Challenges?. Biomedicines, 2021, 9, 1687.	1.4	31
416	The first reported case of trastuzumab induced interstitial lung disease associated with anti-neutrophil cytoplasmic antibody vasculitis â€“ A case report and a prospective cohort study on the usefulness of neutrophil derived biomarkers in monitoring vasculitis disease activity during follow-up. Breast, 2021, 61, 35-42.	0.9	6

#	Article	IF	Citations
417	Her2-Positive Cancers and Antibody-Based Treatment: State of the Art and Future Developments. Cancers, 2021, 13, 5771.	1.7	6
418	China's Hainan Free Trade Port: Medical Laws and Policy Reform. Frontiers in Public Health, 2021, 9, 764977.	1.3	5
419	The Immune Landscape of Breast Cancer: Strategies for Overcoming Immunotherapy Resistance. Cancers, 2021, 13, 6012.	1.7	26
420	YES1 as a Therapeutic Target for HER2-Positive Breast Cancer after Trastuzumab and Trastuzumab-Emtansine (T-DM1) Resistance Development. International Journal of Molecular Sciences, 2021, 22, 12809.	1.8	6
421	Antibody-drug conjugates in treating older patients suffering from cancer: what is the real value?. Human Vaccines and Immunotherapeutics, 2024, 17, 5575-5578.	1.4	2
422	Antibody drug conjugates in non-small cell lung cancer: An emerging therapeutic approach. Lung Cancer, 2022, 163, 59-68.	0.9	17
424	Protease-sensitive Linkers. RSC Drug Discovery Series, 2021, , 173-212.	0.2	0
425	Surrogate endpoints for early-stage breast cancer: a review of the state of the art, controversies, and future prospects. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110595.	1.4	10
426	Trastuzumab Deruxtecan Targeting HER2-expressing Cancers with a DXd-ADC System Consisting of a Novel Protease-sensitive Linker and DNA Topoisomerase I Inhibitor with a Hydroxyl Group. RSC Drug Discovery Series, 2021, , 422-450.	0.2	2
427	Antibody-drug conjugates: Resurgent anticancer agents with multi-targeted therapeutic potential. , 2022, 236, 108106.		16
428	Trastuzumab emtansine for patients with nonâ€“small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations. European Journal of Cancer, 2022, 162, 99-106.	1.3	30
429	Impacts of clinicopathological factors on efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer. Breast, 2022, 61, 136-144.	0.9	10
430	Brazilian Group of Gastrointestinal Tumoursâ€™ consensus guidelines for the management of gastric cancer. Ecancermedicalscience, 2020, 14, 1126.	0.6	3
432	Multichannel dual protein sensing using amphiphilic supramolecular assemblies. Chemical Communications, 2021, 57, 12828-12831.	2.2	1
433	Updates in HER2-Positive and Triple-Negative Breast Cancers. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 605-609.	2.3	2
434	Antibody-drug conjugates in HER2-positive breast cancer. Chinese Medical Journal, 2022, 135, 261-267.	0.9	21
435	A Small Moleculeâ€“Drug Conjugate (SMDC) Consisting of a Modified Camptothecin Payload Linked to an Î±VÃŸ3 Binder for the Treatment of Multiple Cancer Types. Cancers, 2022, 14, 391.	1.7	12
436	Updated Austrian treatment algorithm in HER2+ metastatic breast cancer. Wiener Klinische Wochenschrift, 2022, 134, 63-72.	1.0	1

#	Article	IF	Citations
437	Aiming at a Tailored Cure for ERBB2-Positive Metastatic Breast Cancer. JAMA Oncology, 2022, 8, 629.	3.4	18
439	Clinical Trial Eligibility Criteria and Recently Approved Cancer Therapies for Patients With Brain Metastases. Frontiers in Oncology, 2021, 11, 780379.	1.3	7
440	CT Findings From Interstitial Lung Diseases in Patients With Metastatic Breast Cancer Treated With Fam-Trastuzumab Deruxtecan: A Single Institutional Experience. Journal of Breast Cancer, 2022, 25, 49.	0.8	4
441	Real-World Evidence of Trastuzumab, Pertuzumab, and Docetaxel Combination as a First-Line Treatment for Korean Patients with HER2-Positive Metastatic Breast Cancer. Cancer Research and Treatment, 2022, 54, 1130-1137.	1.3	4
442	Hormonal and Targeted Treatments in Breast Cancer. , 2022, , 443-463.		3
443	Intramedullary spinal cord metastasis to the cauda equina in a patient with HER2-positive metastatic breast cancer: A case report. Breast Disease, 2022, 41, 155-161.	0.4	2
445	Antibody-drug conjugates: A promising novel therapeutic approach in lung cancer. Lung Cancer, 2022, 163, 96-106.	0.9	35
446	Human Epidermal Growth Factor Receptor 2â€“Mutant Nonâ€“Small-Cell Lung Cancer: Continued Progress But Challenges Remain. Journal of Clinical Oncology, 2022, 40, 693-697.	0.8	1
447	Clinical Potential of miR-451 and miR-506 as a Prognostic Biomarker in Patients with Breast Cancer. Journal of Healthcare Engineering, 2022, 2022, 1-6.	1.1	6
448	Pathogenesis of Triple-Negative Breast Cancer. Annual Review of Pathology: Mechanisms of Disease, 2022, 17, 181-204.	9.6	132
449	ABC6 Consensus: Assessment by a Group of German Experts. Breast Care, 2022, 17, 90-100.	0.8	6
450	Targeting HER2+ Breast Cancer Brain Metastases: A Review of Brain-Directed HER2-Directed Therapies. CNS Drugs, 2022, 36, 167-179.	2.7	6
451	Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the lines. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592110666.	1.4	16
452	Bone-Specific Enhancement of Antibody Therapy for Breast Cancer Metastasis to Bone. ACS Central Science, 2022, 8, 312-321.	5.3	4
453	TROP-2, Nectin-4, GPNMB, and B7-H3 Are Potentially Therapeutic Targets for Anaplastic Thyroid Carcinoma. Cancers, 2022, 14, 579.	1.7	4
454	Novel development strategies and challenges for anti-Her2 antibody-drug conjugates. Antibody Therapeutics, 2022, 5, 18-29.	1.2	8
455	Therapeutic Potential of MF-TTZ-MMAE, a Site-Specifically Conjugated Antibody-Drug Conjugate, for the Treatment of HER2-Overexpressing Breast Cancer. Bioconjugate Chemistry, 2022, 33, 418-426.	1.8	3
456	A review on recent synthetic routes and computational approaches for antibody drug conjugation developments used in anti-cancer therapy. Journal of Molecular Structure, 2022, 1256, 132524.	1.8	0

#	Article	IF	Citations
457	Antibodyâ€“Drug Conjugates as an Emerging Therapy in Oncodermatology. Cancers, 2022, 14, 778.	1.7	13
458	Quantitative Parameters of Diffusion Spectrum Imaging: HER2 Status Prediction in Patients With Breast Cancer. Frontiers in Oncology, 2022, 12, 817070.	1.3	10
459	Efficacy of CT-P6 (trastuzumab biosimilar) versus reference trastuzumab in combination with pertuzumab in HER2-positive early-stage breast cancer: Preclinical and real-life clinical data. Breast, 2022, 62, 1-9.	0.9	6
460	Challenges and opportunities in metastatic breast cancer treatments: Nano-drug combinations delivered preferentially to metastatic cells may enhance therapeutic response. , 2022, 236, 108108.		25
461	Roles of Podoplanin in Malignant Progression of Tumor. Cells, 2022, 11, 575.	1.8	29
462	Emerging new therapeutic antibody derivatives for cancer treatment. Signal Transduction and Targeted Therapy, 2022, 7, 39.	7.1	158
463	Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients With Cancer With or Without Mutations in Homologous Recombination Repair Genes. JCO Precision Oncology, 2022, 6, e2100456.	1.5	11
464	Ocular Toxicity in Breast Cancer Management: Manual for The Oncologist. Clinical Breast Cancer, 2022, 22, 289-299.	1.1	3
465	Metastatic Parotid Gland Carcinoma With ERBB2 Amplification With Complete Response to Famâ€Trastuzumab Deruxtecan. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 102-104.	2.3	2
466	Anti-HER2 therapy in metastatic breast cancer: many choices and future directions. Cancer and Metastasis Reviews, 2022, 41, 193-209.	2.7	23
467	Update Breast Cancer 2021 Part 5 â€“ Advanced Breast Cancer. Geburtshilfe Und Frauenheilkunde, 2022, 82, 215-225.	0.8	6
468	DS-7300a, a DNA Topoisomerase I Inhibitor, DXd-Based Antibodyâ€“Drug Conjugate Targeting B7-H3, Exerts Potent Antitumor Activities in Preclinical Models. Molecular Cancer Therapeutics, 2022, 21, 635-646.	1.9	19
469	Antibodyâ€“Pattern Recognition Receptor Agonist Conjugates: A Promising Therapeutic Strategy for Cancer. Advanced Biology, 2022, , 2101065.	1.4	4
470	Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive breast cancer who failed or progressed on prior trastuzumab and/or lapatinib (LUX-Breast 2): an open-label, multicenter, phase II trial. Breast Cancer Research and Treatment, 2022, 192, 593-602.	1.1	5
471	FDA Approval Summary: Margetuximab plus Chemotherapy for Advanced or Metastatic HER2-Positive Breast Cancer. Clinical Cancer Research, 2022, 28, 1487-1492.	3.2	23
472	Heterogenous and Low Expression of HER2 in Breast Cancer Overcome by DS-8201a in a Heavily Treated Patient: Case Report and Review of the Literature. Clinical Medicine Insights: Oncology, 2022, 16, 117955492110728.	0.6	2
473	HER2 Testing in Metastatic Breast Cancer â€“ Is Reflex ISH Testing Necessary on HER2 IHC-Equivocal (2+) Cases?. SSRN Electronic Journal, 0, , .	0.4	0
474	Prognostic impact of body mass index (BMI) in HER2+ breast cancer treated with anti-HER2 therapies: from preclinical rationale to clinical implications. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210791.	1.4	3

#	Article	IF	Citations
475	Emerging treatment strategies for metastatic triple-negative breast cancer. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210869.	1.4	15
476	Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. Cancer Research Statistics and Treatment, 2022, 5, 195.	0.1	0
477	Emetogenicity of Antibody-Drug Conjugates (ADCs) in Solid Tumors with a Focus on Trastuzumab Deruxtecan: Insights from an Italian Expert Panel. Cancers, 2022, 14, 1022.	1.7	10
478	Breast cancer management in 2021: A primer for the obstetrics and gynecology. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2022, 82, 30-45.	1.4	18
479	Associations of HER2 Mutation With Immune-Related Features and Immunotherapy Outcomes in Solid Tumors. Frontiers in Immunology, 2022, 13, 799988.	2.2	7
480	Characteristics, Clinical Differences and Outcomes of Breast Cancer Patients with Negative or Low HER2 Expression. Clinical Breast Cancer, 2022, 22, 391-397.	1.1	34
481	Intracranial Response Rate in Patients with Breast Cancer Brain Metastases after Systemic Therapy. Cancers, 2022, 14, 965.	1.7	2
482	Glycans as Targets for Drug Delivery in Cancer. Cancers, 2022, 14, 911.	1.7	19
483	Antibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor Family in Cancers. Frontiers in Molecular Biosciences, 2022, 9, 847835.	1.6	41
484	Durable Effect of Pyrotinib and Metronomic Vinorelbine in HER2-Positive Breast Cancer With Leptomeningeal Disease: A Case Report and Literature Review. Frontiers in Oncology, 2022, 12, 811919.	1.3	4
485	New antibody-drug conjugates (ADCs) in breast cancerâ€”an overview of ADCs recently approved and in later stages of development. Exploration of Targeted Anti-tumor Therapy, 0, , 27-36.	0.5	15
486	Molecular profiling leading to personalized treatment in breast cancer. Memo - Magazine of European Medical Oncology, 0, , 1.	0.3	1
487	Two cases of trastuzumab deruxtecanâ€‐induced interstitial lung disease in advanced breast cancer. Respirology Case Reports, 2022, 10, e0928.	0.3	3
488	Association of HER-2/CEP17 Ratio and HER-2 Copy Number With pCR Rate in HER-2-Positive Breast Cancer After Dual-Target Neoadjuvant Therapy With Trastuzumab and Pertuzumab. Frontiers in Oncology, 2022, 12, 819818.	1.3	3
489	Bystander effect of antibodyâ€“drug conjugates: fact or fiction?. Current Oncology Reports, 2022, 24, 809-817.	1.8	35
490	Evolving management of HER2+ breast cancer brain metastases and leptomeningeal disease. Journal of Neuro-Oncology, 2022, 157, 249-269.	1.4	9
491	Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. New England Journal of Medicine, 2022, 386, 1143-1154.	13.9	474
492	Diagnosis and Treatment of ERBB2-Positive Metastatic Colorectal Cancer. JAMA Oncology, 2022, 8, 760.	3.4	35

#	Article	IF	Citations
493	Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma. Molecular Cancer Therapeutics, 2022, 21, 903-913.	1.9	12
495	SEOM-GEINO clinical guideline of systemic therapy and management of brain central nervous system metastases (2021). Clinical and Translational Oncology, 2022, 24, 703-711.	1.2	2
497	mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer. Molecular Cancer Research, 2022, 20, 1108-1121.	1.5	5
498	Underserved groups remain underserved as eligibility criteria routinely exclude them from breast cancer trials. Journal of Clinical Epidemiology, 2022, 147, 132-141.	2.4	5
499	Margetuximab Versus Trastuzumab in Patients With Advanced Breast Cancer: A Cost-effectiveness Analysis. Clinical Breast Cancer, 2022, 22, e629-e635.	1.1	4
500	Antibody drug conjugate: the â€œbiological missileâ€•for targeted cancer therapy. Signal Transduction and Targeted Therapy, 2022, 7, 93.	7.1	361
501	Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)â€“related interstitial lung disease/pneumonitisâ€”Focus on proactive monitoring, diagnosis, and management. Cancer Treatment Reviews, 2022, 106, 102378.	3.4	60
502	Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival. ESMO Open, 2022, 7, 100409.	2.0	25
503	An Innovative Site-Specific Anti-HER2 Antibody-Drug Conjugate with High Homogeneity and Improved Therapeutic Index. OncoTargets and Therapy, 2022, Volume 15, 331-343.	1.0	4
504	Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment. ESMO Open, 2022, 7, 100404.	2.0	65
505	Developments in the Management of Metastatic HER2-Positive Breast Cancer: A Review. Current Oncology, 2022, 29, 2539-2549.	0.9	12
506	HER2 targeted therapy in colorectal cancer: New horizons. Cancer Treatment Reviews, 2022, 105, 102363.	3.4	12
507	Clinical trial data and emerging strategies: HER2-positive breast cancer. Breast Cancer Research and Treatment, 2022, 193, 281-291.	1.1	12
508	Cardioprotection for Anti-HER2 Therapy: Considerations for Primary Prevention and Use in Mildly Reduced Left Ventricular Ejection Fraction. Current Oncology Reports, 2022, 24, 1063-1070.	1.8	3
509	Treatment of small (T1mic, T1a, and T1b) node-negative HER2+ breast cancer â€“ a review of current evidence for and against the use of anti-HER2 treatment regimens. Expert Review of Anticancer Therapy, 2022, 22, 505-522.	1.1	1
510	A Patent Review on FDAâ€Approved Antibodyâ€Drug Conjugates, Their Linkers and Drug Payloads. ChemMedChem, 2022, 17, e202200032.	1.6	29
511	Validity and utility of HER2/ERBB2 copy number variation assessed in liquid biopsies from breast cancer patients: A systematic review. Cancer Treatment Reviews, 2022, 106, 102384.	3.4	12
512	Topoisomerase I inhibitors: Challenges, progress and the road ahead. European Journal of Medicinal Chemistry, 2022, 236, 114304.	2.6	29

#	Article	IF	Citations
513	Central nervous system disease in phase III studies for advanced HER2 positive breast cancer: A review. Breast, 2022, 63, 85-100.	0.9	5
514	Efficacy with Trastuzumab Deruxtecan for Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutation in a Patient with a Poor Performance Status: A Case Report. OncoTargets and Therapy, 2021, Volume 14, 5315-5319.	1.0	2
515	The management of toxicities from immune, targeted and ADCs treatments in patients with urothelial cancer. Urologic Oncology: Seminars and Original Investigations, 2023, 41, 410-419.	0.8	3
516	Antibodyâ€drug conjugates targeting CD248 ⁺ myofibroblasts effectively alleviate renal fibrosis in mice. FASEB Journal, 2022, 36, e22102.	0.2	2
518	Updates on targeting human epidermal growth factor receptor 2-positive breast cancer: what's to know in 2021. Current Opinion in Obstetrics and Gynecology, 2022, 34, 41-45.	0.9	5
520	Neuroendocrine Neoplasms of the Breast: The Latest WHO Classification and Review of the Literature. Cancers, 2022, 14, 196.	1.7	4
521	Comparative Study on the Efficacy and Exposure of Molecular Target Agents in Nonâ€“small Cell Lung Cancer PDX Models with Driver Genetic Alterations. Molecular Cancer Therapeutics, 2022, 21, 359-370.	1.9	3
522	Eribulin-trastuzumab combination in HER2-positive metastatic breast cancer: updated results from a Russian observational study. Meditsinskiy Sovet, 2021, , 36-46.	0.1	0
523	No evidence of disease versus residual disease in long-term responders to first-line HER2-targeted therapy for metastatic breast cancer. British Journal of Cancer, 2022, 126, 881-888.	2.9	5
524	Preventing and Overcoming Resistance to PARP Inhibitors: A Focus on the Clinical Landscape. Cancers, 2022, 14, 44.	1.7	16
525	Novel ADCs and Strategies to Overcome Resistance to Anti-HER2 ADCs. Cancers, 2022, 14, 154.	1.7	30
527	Current state of clinical development of TROP2-directed antibodyâ€“drug conjugates for triple-negative breast cancer. Memo - Magazine of European Medical Oncology, 2022, 15, 129-132.	0.3	3
528	Antibody Drug Conjugates in Glioblastoma â€“ Is There a Future for Them?. Frontiers in Oncology, 2021, 11, 718590.	1.3	14
530	Efficacy and safety of camrelizumab in combination with trastuzumab and chemotherapy as the first-line treatment for patients with HER2-positive advanced gastric cancer. Journal of Gastrointestinal Oncology, 2022, 13, 548-558.	0.6	7
532	Therapeutic Advances and Challenges in the Management of HER2-Positive Gastroesophageal Cancers. Diseases (Basel, Switzerland), 2022, 10, 23.	1.0	1
533	Novel Therapies for the Treatment of HER2-Positive Advanced Breast Cancer: A Canadian Perspective. Current Oncology, 2022, 29, 2720-2734.	0.9	9
534	Advancing antibody-drug conjugates in gynecological malignancies: myth or reality?. Exploration of Targeted Anti-tumor Therapy, 0, , 149-171.	0.5	3
535	Tucatinib has Selective Activity in HER2-Positive Cancers and Significant Combined Activity with Approved and Novel Breast Cancerâ€“Targeted Therapies. Molecular Cancer Therapeutics, 2022, 21, 751-761.	1.9	10

#	Article	IF	Citations
536	An overview of the preclinical discovery and development of trastuzumab deruxtecan: a novel gastric cancer therapeutic. Expert Opinion on Drug Discovery, 2022, 17, 427-436.	2.5	2
537	Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/â˜' trastuzumab in patients with breast cancer brain metastases. Npj Breast Cancer, 2022, 8, 50.	2.3	17
538	Antibody-Drug Conjugates as an Adjuvant Therapy for Human Epidermal Growth Factor Receptor 2â€"Positive Early Breast Cancer. Journal of Clinical Oncology, 2022, 40, 2066-2067.	0.8	1
539	Ribociclib in the Treatment of Hormone-Receptor Positive/HER2-Negative Advanced and Early Breast Cancer: Overview of Clinical Data and Patients Selection. Breast Cancer: Targets and Therapy, 2022, Volume 14, 101-111.	1.0	2
540	Design and synthesis of novel 7-ethyl-10-fluoro-20-O-(cinnamic acid ester)-camptothecin derivatives as potential high selectivity and low toxicity topoisomerase I inhibitors for hepatocellular carcinoma. Biochemical Pharmacology, 2022, 200, 115049.	2.0	5
541	A Defucosylated Mouse Anti-CD10 Monoclonal Antibody (31-mG_{2a}-f) Exerts Antitumor Activity in a Mouse Xenograft Model of CD10-Overexpressed Tumors. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2022, 41, 59-66.	0.8	11
543	Therapeutic Landscape of Human Epidermal Growth Factor Receptor 2â€"Positive Breast Cancer. Cancer Control, 2022, 29, 107327482210992.	0.7	11
544	Molecular Engineering of Surface Functional Groups Enabling Clinical Translation of Nanoparticleâ€"Drug Conjugates. Chemistry of Materials, 2022, 34, 5344-5355.	3.2	8
545	Profile of Margetuximab: Evidence to Date in the Targeted Treatment of Metastatic HER2-positive Breast Cancer. OncoTargets and Therapy, 2022, Volume 15, 471-478.	1.0	7
546	Dose Finding in Oncology: What is Impeding Coming of Age?. Pharmaceutical Research, 2022, , 1.	1.7	1
547	Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives. Cancers, 2022, 14, 2136.	1.7	21
549	Antibody-drug conjugates: beyond current approvals and potential future strategies. Exploration of Targeted Anti-tumor Therapy, 0, , 252-277.	0.5	11
550	Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial. Future Oncology, 2022, 18, 2351-2360.	1.1	22
551	Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy. Drug Delivery, 2022, 29, 1335-1344.	2.5	72
552	AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2022. Breast Care, 2022, 17, 421-429.	0.8	9
553	Trastuzumab Deruxtecan in Nonâ€"Small-Cell Lung Cancer. New England Journal of Medicine, 2022, 386, 1769-1771.	13.9	3
554	A role of FDG-PET/CT for response evaluation in metastatic breast cancer?. Seminars in Nuclear Medicine, 2022, 52, 520-530.	2.5	19
555	ESMO 2021â€"my topÂthreeÂabstracts in breast cancer. Memo - Magazine of European Medical Oncology, 2022, , 1-3.	0.3	1

#	Article	IF	Citations
556	HER2 testing in metastatic breast cancer â€“ Is reflex ISH testing necessary on HER2 IHC-equivocal (2+) cases?. Annals of Diagnostic Pathology, 2022, 59, 151953.	0.6	0
557	Distinct clinical and somatic mutational features of breast tumors with high-, low-, or non-expressing human epidermal growth factor receptor 2 status. BMC Medicine, 2022, 20, 142.	2.3	55
559	Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer. International Journal of Molecular Sciences, 2022, 23, 5476.	1.8	2
560	Field carcinogenesis and biological significance of the potential of the bystander effect: carcinogenesis, therapeutic response, and tissue regeneration. Surgery Today, 2022, , .	0.7	1
561	Cancer therapeutics-related cardiovascular dysfunction: Basic mechanisms and clinical manifestation. Journal of Cardiology, 2023, 81, 253-259.	0.8	2
562	Incidence of adverse events with therapies targeting HER2-positive metastatic breast cancer: a literature review. Breast Cancer Research and Treatment, 2022, 194, 1-11.	1.1	11
563	Current status and future prospects of antibodyâ€“drug conjugates in urological malignancies. International Journal of Urology, 2022, 29, 1100-1108.	0.5	3
564	Integrating radiation therapy with targeted treatments for breast cancer: From bench to bedside. Cancer Treatment Reviews, 2022, 108, 102417.	3.4	11
566	The History of Early Breast Cancer Treatment. Genes, 2022, 13, 960.	1.0	16
567	Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer: ASCO Guideline Update. Journal of Clinical Oncology, 2022, 40, 2612-2635.	0.8	60
568	Cell Surface Markers and Their Targeted Drugs in Breast Cancer. Current Protein and Peptide Science, 2022, 23, .	0.7	0
569	Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer. Laboratory Investigation, 2022, 102, 1101-1108.	1.7	53
570	The current management and biomarkers of immunotherapy in advanced gastric cancer. Medicine (United States), 2022, 101, e29304.	0.4	16
571	Comparison of adverse effects of trastuzumab with other drug combinations for the treatment of breast cancer: A review. Indian Journal of Physiology and Pharmacology, 0, 66, 1-15.	0.4	1
572	Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial. Neuro-Oncology, 2023, 25, 157-166.	0.6	92
573	Research Progress of Antibodyâ€“Drug Conjugate Therapy for Advanced Gastric Cancer. Frontiers in Oncology, 0, 12, .	1.3	4
574	Systemic Therapy Type and Timing Effects on Radiation Necrosis Risk in HER2+ Breast Cancer Brain Metastases Patients Treated With Stereotactic Radiosurgery. Frontiers in Oncology, 0, 12, .	1.3	4
576	Clinical Practices and Institutional Protocols on Prophylaxis, Monitoring, and Management of Selected Adverse Events Associated with Trastuzumab Deruxtecan. Oncologist, 2022, 27, 637-645.	1.9	12

#	Article	IF	Citations
577	Molecular Assessment of HER2 to Identify Signatures Associated with Therapy Response in HER2-Positive Breast Cancer. Cancers, 2022, 14, 2795.	1.7	7
578	Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. New England Journal of Medicine, 2022, 387, 9-20.	13.9	854
579	Precision Medicine in Cholangiocarcinoma: Past, Present, and Future. Life, 2022, 12, 829.	1.1	8
580	Characteristics of patients with brain metastases from human epidermal growth factor receptor 2-positive breast cancer: subanalysis of Brain Metastases in Breast Cancer Registry. ESMO Open, 2022, 7, 100495.	2.0	3
581	Perioperative HER2 targeted treatment in early stage HER2-positive breast cancer. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211065.	1.4	3
582	An overview of resistance to chemotherapy in osteosarcoma and future perspectives. Cancer Drug Resistance (Alhambra, Calif), 2022, 5, 762-93.	0.9	10
583	Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Moving Into a New Era. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, , 82-92.	1.8	6
585	Research Trend of Publications Concerning Antibody-Drug Conjugate in Solid Cancer: A Bibliometric Study. Frontiers in Pharmacology, 0, 13, .	1.6	4
586	Application of histology-agnostic treatments in metastatic colorectal cancer. Digestive and Liver Disease, 2022, 54, 1291-1303.	0.4	5
588	Intratumoral delivery of dendritic cells plus anti-HER2 therapy triggers both robust systemic antitumor immunity and complete regression in HER2 mammary carcinoma. , 2022, 10, e004841.		6
589	Recently approved treatment options for patients with metastatic triple-negative and HER2-neu-positive breast cancer. Journal of Investigative Medicine, 2022, 70, 1329-1341.	0.7	2
591	Trastuzumab deruxtecan: An antibody-drug conjugate embracing its destiny in breast cancer. Cell Reports Medicine, 2022, 3, 100668.	3.3	4
592	Breast Cancer Epidemiology and Contemporary Breast Cancer Care: A Review of the Literature and Clinical Applications. Clinical Obstetrics and Gynecology, 2022, 65, 461-481.	0.6	6
593	Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer. Frontiers in Oncology, 0, 12, .	1.3	39
594	Targeting Cell Cycle Progression in HER2+ Breast Cancer: An Emerging Treatment Opportunity. International Journal of Molecular Sciences, 2022, 23, 6547.	1.8	11
595	Systemic Treatment of Breast Cancer. 1st Central-Eastern European Professional Consensus Statement on Breast Cancer. Pathology and Oncology Research, 0, 28, .	0.9	12
596	Current State of Targeted Therapy and Immunotherapy in Advanced Gastric and Gastro-oesophageal Cancers. Touch Reviews in Oncology & Haematology, 2022, 18, 16.	0.1	0
597	TOP1 inhibition induces bifurcated JNK/MYC signaling that dictates cancer cell sensitivity. International Journal of Biological Sciences, 2022, 18, 4203-4218.	2.6	0

#	Article	IF	Citations
598	Tackling the clinical complexity of breast cancer. Drugs in Context, 0, 11, 1-5.	1.0	3
599	Pertuzumab retreatment for HER2â€positive advanced breast cancer: A randomized, openâ€label phase III study (PRECIOUS). Cancer Science, 2022, 113, 3169-3179.	1.7	8
600	Therapeutic Response Monitoring with 89Zr-DFO-Pertuzumab in HER2-Positive and Trastuzumab-Resistant Breast Cancer Models. Pharmaceutics, 2022, 14, 1338.	2.0	3
601	Trastuzumab Deruxtecan-Induced Interstitial Lung Disease/Pneumonitis in ERBB2-Positive Advanced Solid Malignancies: A Systematic Review. Drugs, 2022, 82, 979-987.	4.9	35
602	Phase I Trial of a Novel Anti-HER2 Antibodyâ€“Drug Conjugate, ARX788, for the Treatment of HER2-Positive Metastatic Breast Cancer. Clinical Cancer Research, 2022, 28, 4212-4221.	3.2	19
603	Immunological Landscape of HER-2 Positive Breast Cancer. Cancers, 2022, 14, 3167.	1.7	3
604	From Anti-HER-2 to Anti-HER-2-CAR-T Cells: An Evolutionary Immunotherapy Approach for Gastric Cancer. Journal of Inflammation Research, 0, Volume 15, 4061-4085.	1.6	1
605	Structureâ€“Activity Relationships of Antibody-Drug Conjugates: A Systematic Review of Chemistry on the Trastuzumab Scaffold. Bioconjugate Chemistry, 2022, 33, 1241-1253.	1.8	13
607	Breast cancer brain metastasis: Current evidence and future directions. Cancer Medicine, 2023, 12, 1007-1024.	1.3	18
608	Molecular perspective on targeted therapy in breast cancer: a review of current status. , 2022, 39, .		12
609	Resistance to TKIs in EGFR-Mutated Non-Small Cell Lung Cancer: From Mechanisms to New Therapeutic Strategies. Cancers, 2022, 14, 3337.	1.7	21
610	Defucosylated mouseâ€‘dog chimeric antiâ€‘HER2 monoclonal antibody exerts antitumor activities in mouse xenograft models of canine tumors. Oncology Reports, 2022, 48, .	1.2	6
611	Beyond HER2: Targeting the ErbB receptor family in breast cancer. Cancer Treatment Reviews, 2022, 109, 102436.	3.4	13
612	Rethinking breast cancer follow-up based on individual risk and recurrence management. Cancer Treatment Reviews, 2022, 109, 102434.	3.4	14
613	Monomethyl auristatin antibody and peptide drug conjugates for trimodal cancer chemo-radio-immunotherapy. Nature Communications, 2022, 13, .	5.8	14
614	Real-world outcomes in patients with brain metastases secondary to HER2-positive breast cancer: An Australian multi-centre registry-based study. Clinical Breast Cancer, 2022, , .	1.1	0
615	Leptomeningeal Metastases: New Opportunities in the Modern Era. Neurotherapeutics, 2022, 19, 1782-1798.	2.1	9
616	Histology-agnostic approvals for antibodyâ€“drug conjugates in solid tumours: is the time ripe?. European Journal of Cancer, 2022, 171, 25-42.	1.3	9

#	Article	IF	Citations
617	Discovery of novel polyamide-pyrrolobenzodiazepine hybrids for antibody-drug conjugates. Bioorganic and Medicinal Chemistry Letters, 2022, 72, 128876.	1.0	1
618	Phase II study of intrathecal administration of trastuzumab in patients with HER2-positive breast cancer with leptomeningeal metastasis. Neuro-Oncology, 2023, 25, 365-374.	0.6	23
619	Designing antibodies as therapeutics. Cell, 2022, 185, 2789-2805.	13.5	65
620	Hitting the target in HER2 mutant cancers. Nature Cancer, 2022, 3, 785-786.	5.7	1
621	Neurospora crassa is a potential source of anti-cancer agents against breast cancer. Breast Cancer, 2022, 29, 1032-1041.	1.3	2
622	Efficacy and safety of pyrotinibâ€containing regimen in the patients with HER2â€positive metastatic breast cancer: A multicenter realâ€world study. Cancer Medicine, 0, , .	1.3	4
623	Is antibody-drug conjugate a rising star for clinical treatment of solid tumors? A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2022, 177, 103758.	2.0	2
624	S Phase. , 2022, , .		0
625	Trastuzumab Deruxtecan, Antibodyâ€“Drug Conjugate Targeting HER2, Is Effective in Pediatric Malignancies: A Report by the Pediatric Preclinical Testing Consortium. Molecular Cancer Therapeutics, 2022, 21, 1318-1325.	1.9	6
626	Current challenges and unmet needs in treating patients with human epidermal growth factor receptor 2-positive advanced breast cancer. Breast, 2022, 66, 145-156.	0.9	3
627	Precision Medicine in Metastatic Colorectal Cancer: Targeting ERBB2 (HER-2) Oncogene. Cancers, 2022, 14, 3718.	1.7	6
628	Customized Multifunctional Peptide Hydrogel Scaffolds for CAR-T-Cell Rapid Proliferation and Solid Tumor Immunotherapy. ACS Applied Materials & Interfaces, 2022, 14, 37514-37527.	4.0	12
629	Overcoming Resistance to HER2-Directed Therapies in Breast Cancer. Cancers, 2022, 14, 3996.	1.7	24
630	Cost-Effectiveness Analysis of Trastuzumab Deruxtecan versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer in the USA. Advances in Therapy, 2022, 39, 4583-4593.	1.3	11
631	Tailoring antiHer2 treatment strategies in breast cancer and beyond. Current Problems in Cancer, 2022, 46, 100892.	1.0	4
632	Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial. Nature Medicine, 2022, 28, 1840-1847.	15.2	152
633	Case Report: Prolonged clinical benefit with sequential trastuzumab-containing treatments in a patient with advanced extramammary Paget disease of the groin. Frontiers in Oncology, 0, 12, .	1.3	5
634	Antibody drug conjugates (ADCs): an expanding rational treatment paradigm in breast cancer (CME) Tj ETQq1 1 0.784314 rgBT /Over	0.0	0

#	Article	IF	Citations
635	Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer. ESMO Open, 2022, 7, 100553.	2.0	32
636	2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). European Heart Journal Cardiovascular Imaging, 2022, 23, e333-e465.	0.5	97
637	Comparison of HercepTestâ„¢ mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2/neu (4B5) in breast cancer: correlation with HER2 amplification and HER2 low status. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 481, 685-694.	1.4	28
638	Pan-cancer distribution of cleaved cell-surface amphiregulin, the target of the GMF-1A3 antibody drug conjugate. Antibody Therapeutics, 2022, 5, 226-231.	1.2	0
639	Targeting the complexity of ERBB2 biology in gastroesophageal carcinoma. Annals of Oncology, 2022, 33, 1134-1148.	0.6	6
640	Advances in neoadjuvant therapy for HER2-positive breast cancers: a narrative review. Gland Surgery, 2022, 11, 1415-1423.	0.5	3
641	The Potential of Topoisomerase Inhibitor-Based Antibodyâ€“Drug Conjugates. Pharmaceutics, 2022, 14, 1707.	2.0	12
642	An update on antibodyâ€“drug conjugates in urothelial carcinoma: state of the art strategies and what comes next. Cancer Chemotherapy and Pharmacology, 2022, 90, 191-205.	1.1	4
643	2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). European Heart Journal, 2022, 43, 4229-4361.	1.0	705
644	Safety and efficacy profile of Trastuzumab deruxtecan in solid cancer: pooled reanalysis based on clinical trials. BMC Cancer, 2022, 22, .	1.1	1
645	Racial disparities in breast cancer preclinical and clinical models. Breast Cancer Research, 2022, 24, .	2.2	5
646	Potential of antibodyâ€“drug conjugates (ADCs) for cancer therapy. Cancer Cell International, 2022, 22, .	1.8	36
647	Prognostic and predictive biomarkers with therapeutic targets in breast cancer: A 2022 update on current developments, evidence, and recommendations. Journal of Oncology Pharmacy Practice, 2023, 29, 1343-1360.	0.5	3
648	Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies. ESMO Open, 2022, 7, 100554.	2.0	73
649	Predictive biomarkers for molecularly targeted therapies and immunotherapies in breast cancer. Archives of Pharmacal Research, 2022, 45, 597-617.	2.7	6
650	An overview of epithelial growth factor receptor (EGFR) inhibitors in cancer therapy. Chemico-Biological Interactions, 2022, 366, 110108.	1.7	20
651	Sacituzumab govitecan: past, present and future of a new antibodyâ€“drug conjugate and future horizon. Future Oncology, 2022, 18, 3199-3215.	1.1	10
652	Genomic Classification of HER2-Positive Patients With 80-Gene and 70-Gene Signatures Identifies Diversity in Clinical Outcomes With HER2-Targeted Neoadjuvant Therapy. JCO Precision Oncology, 2022, , .	1.5	3

#	Article	IF	Citations
653	Final results of the global and Asia cohorts of KAMILLA, a phase IIIB safety trial of trastuzumab emtansine in patients with HER2-positive advanced breast cancer. ESMO Open, 2022, 7, 100561.	2.0	6
654	Enhertu (Fam-trastuzumab-deruxtecan-nxki) â€“ Revolutionizing treatment paradigm for HER2-Low breast cancer. Annals of Medicine and Surgery, 2022, 82, 104665.	0.5	2
655	Trastuzumab-deruxtecan: New treatment, familiar complications. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 0, , 1-2.	0.2	0
656	GPNMB: a potent inducer of immunosuppression in cancer. Oncogene, 2022, 41, 4573-4590.	2.6	11
657	Can EGFR be a therapeutic target in breast cancer?. Biochimica Et Biophysica Acta: Reviews on Cancer, 2022, 1877, 188789.	3.3	14
658	Refining the definition of <scp>HER2</scp>â€low class in invasive breast cancer. Histopathology, 2022, 81, 770-785.	1.6	13
659	Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications. Journal of Experimental and Clinical Cancer Research, 2022, 41, .	3.5	35
661	Breast cancer: an upâ€toâ€date review and future perspectives. Cancer Communications, 2022, 42, 913-936.	3.7	70
662	TP53-positive clones are responsible for drug-tolerant persister and recurrence of HER2-positive breast cancer. Breast Cancer Research and Treatment, 2022, 196, 255-266.	1.1	3
664	Effect of Trastuzumab Deruxtecan on <scp>QT</scp>/<scp>QTc</scp> Interval and Pharmacokinetics in <scp>HER2â€Positive</scp> or <scp>HER2â€Low</scp> Metastatic/Unresectable Breast Cancer. Clinical Pharmacology and Therapeutics, 2023, 113, 160-169.	2.3	4
665	B7-H3 as a Therapeutic Target in Advanced Prostate Cancer. European Urology, 2023, 83, 224-238.	0.9	18
666	Clinical Profile and Outcome of Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer With Brain Metastases: Real-World Experience. JCO Global Oncology, 2022, , .	0.8	1
667	Radiotherapy or systemic therapy versus combined therapy in patients with brain metastases: a propensity-score matched study. Journal of Neuro-Oncology, 0, , .	1.4	4
668	Computational Studies on Antibody Drug Conjugates (ADCs) for Precision Oncology. ChemistrySelect, 2022, 7, .	0.7	1
669	The emergence of AntibodyPlus: the future trend of antibody-based therapeutics. Antibody Therapeutics, 2022, 5, 280-287.	1.2	3
670	IKZF3 amplification frequently occurs in HER2-positive breast cancer and is a potential therapeutic target. , 2022, 39, .		2
671	Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases. Clinical Cancer Research, 2023, 29, 174-182.	3.2	32
672	Evaluation of lung adverse events with trastuzumab using the Japanese pharmacovigilance database. , 2022, 39, .		3

#	Article	IF	Citations
673	Sacituzumab govitecan and other antibody-drug conjugates targeting trophoblast cell-surface antigen 2 (Trop-2) in breast cancer. Annals of Translational Medicine, 2022, 10, 1031-1031.	0.7	2
674	Interstitial lung disease associated with anti-HER2 anti-body drug conjugates: results from clinical trials and the WHO's pharmacovigilance database. Expert Review of Clinical Pharmacology, 2022, 15, 1351-1361.	1.3	8
675	Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer. Frontiers in Pharmacology, 0, 13, .	1.6	8
676	Current landscape of personalized clinical treatments for triple-negative breast cancer. Frontiers in Pharmacology, 0, 13, .	1.6	11
677	Prognostic significance of HER2 status evaluation using immunohistochemistry in patients with urothelial carcinoma of the bladder: A retrospective singleâ€'center experience. Experimental and Therapeutic Medicine, 2022, 24, .	0.8	2
678	Safety of trastuzumab deruxtecan: A metaâ€'analysis and pharmacovigilance study. Journal of Clinical Pharmacy and Therapeutics, 2022, 47, 1837-1844.	0.7	9
679	Nanoparticles (NPs)-mediated systemic mRNA delivery to reverse trastuzumab resistance for effective breast cancer therapy. Acta Pharmaceutica Sinica B, 2023, 13, 955-966.	5.7	6
680	HER2-Low Breast Cancer: Where Are We?. Breast Care, 2022, 17, 533-545.	0.8	12
682	Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis. Cancer Discovery, 2022, 12, 2754-2762.	7.7	30
683	Development of Antibody-Drug Conjugates: Future Perspective Towards Solid Tumor Treatment. Anti-Cancer Agents in Medicinal Chemistry, 2023, 23, 642-657.	0.9	1
684	An Insight into Molecular Targets of Breast Cancer Brain Metastasis. International Journal of Molecular Sciences, 2022, 23, 11687.	1.8	5
685	Targeting breast and pancreatic cancer metastasis using a dual-cadherin antibody. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	6
686	Imaging of Drug-Related Pneumonitis in Oncology. Seminars in Respiratory and Critical Care Medicine, 0, , .	0.8	0
687	Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. Journal of Hematology and Oncology, 2022, 15, .	6.9	59
688	The Present and Future of Clinical Management in Metastatic Breast Cancer. Journal of Clinical Medicine, 2022, 11, 5891.	1.0	7
689	Biomarkers in Metastatic Colorectal Cancer: Status Quo and Future Perspective. Cancers, 2022, 14, 4828.	1.7	11
690	Resistance to Trastuzumab. Cancers, 2022, 14, 5115.	1.7	23
691	Therapeutic landscape of advanced HER2-positive breast cancer in 2022. , 2022, 39, .		11

#	Article	IF	Citations
692	Recent Advances in Natural Product-Based Hybrids as Anti-Cancer Agents. Molecules, 2022, 27, 6632.	1.7	10
696	Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibodyâ€“Drug Conjugates in Breast Cancer. Cancer Research, 2022, 82, 4670-4679.	0.4	5
697	Immune Checkpoint Inhibitors and Other Immune Therapies in Breast Cancer: A New Paradigm for Prolonged Adjuvant Immunotherapy. Biomedicines, 2022, 10, 2511.	1.4	10
698	Different treatment regimens in breast cancer visceral crisis: A retrospective cohort study. Frontiers in Oncology, 0, 12, .	1.3	4
699	Clinical implication of genetic composition and molecular mechanism on treatment strategies of HER2-positive breast cancers. Frontiers in Oncology, 0, 12, .	1.3	0
700	Prognostic value of human epidermal growth factor receptor 2 status and systemic therapy in breast cancer with brain metastases treated with radiotherapy. Asia-Pacific Journal of Clinical Oncology, 0, , .	0.7	0
703	Management of Brain Metastases from Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Cancer. Cancers, 2022, 14, 5136.	1.7	0
704	Trastuzumab deruxtecan versus trastuzumab emtansine for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: A cost-effectiveness analysis. Breast, 2022, 66, 191-198.	0.9	10
705	Cysteine cathepsins: A long and winding road towards clinics. Molecular Aspects of Medicine, 2022, 88, 101150.	2.7	10
706	Margetuximab and trastuzumab deruxtecan: New generation of anti-HER2 immunotherapeutic agents for breast cancer. Molecular Immunology, 2022, 152, 45-54.	1.0	5
707	Antibody drug conjugates targeting HER2: Clinical development in metastatic breast cancer. Breast, 2022, 66, 217-226.	0.9	17
708	Learn from antibodyâ€“drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy. Experimental Hematology and Oncology, 2022, 11, .	2.0	12
709	Antibody-Drug Conjugates and Tissue-Agnostic Drug Development. Cancer Journal (Sudbury, Mass), 2022, 28, 462-468.	1.0	0
710	Antitumor Activities in Mouse Xenograft Models of Canine Fibroblastic Tumor by Defucosylated Mouse-Dog Chimeric Anti-HER2 Monoclonal Antibody (H77Bf). Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 0, , .	0.8	1
711	Resistance to antibodyâ€drug conjugates in breast cancer: mechanisms and solutions. Cancer Communications, 2023, 43, 297-337.	3.7	18
712	Phase 1 multicenter, dose-expansion study of ARX788 as monotherapy in HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma. Cell Reports Medicine, 2022, 3, 100814.	3.3	9
713	Excellent Response to Fam-Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2â€“Positive Salivary Duct Carcinoma With CNS Metastasis: A Case Report. JCO Precision Oncology, 2022, , .	1.5	1
714	Methods for Estimating Long-Term Outcomes for Trastuzumab Deruxtecan in HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies. Targeted Oncology, 0, , .	1.7	0

#	Article	IF	Citations
715	Antibody-Drug Conjugates in Breast Cancer: What Is Beyond HER2?. Cancer Journal (Sudbury, Mass), 2022, 28, 436-445.	1.0	6
716	Strategies for Mitigating Antibody-Drug Conjugate Related Adverse Events for Precision Therapy. Cancer Journal (Sudbury, Mass), 2022, 28, 496-507.	1.0	1
717	Design and Preclinical Evaluation of a Novel B7-H4â€“Directed Antibodyâ€“Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305. Clinical Cancer Research, 2023, 29, 1086-1101.	3.2	10
718	Antibody-Drug Conjugates in Breast Cancer: Spotlight on HER2. Cancer Journal (Sudbury, Mass), 2022, 28, 423-428.	1.0	4
719	Antibody Drug Conjugates in Lung Cancer. Cancer Journal (Sudbury, Mass), 2022, 28, 429-435.	1.0	0
720	Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer. Genes, 2022, 13, 2065.	1.0	19
721	Unexpected Cardiotoxicity in Patients With HER2-Mutant NSCLC Treated With Trastuzumab Deruxtecan: A Case Report. JTO Clinical and Research Reports, 2022, 3, 100432.	0.6	0
722	Targeting HER2-positive breast cancer: advances and future directions. Nature Reviews Drug Discovery, 2023, 22, 101-126.	21.5	140
724	A multidisciplinary management algorithm for brain metastases. Neuro-Oncology Advances, 2022, 4, .	0.4	3
725	Antibody drug conjugates, targeting cancer-expressed EGFR, exhibit potent and specific antitumor activity. Biomedicine and Pharmacotherapy, 2023, 157, 114047.	2.5	5
726	Association of lesion contour and lesion composition on MR with HER2 status in breast cancer brain metastases. Magnetic Resonance Imaging, 2023, 96, 60-66.	1.0	2
727	Systemic Therapy for Early- and Late-Stage, Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer. Hematology/Oncology Clinics of North America, 2023, 37, 103-115.	0.9	1
728	An anti-EGFR antibody-drug conjugate overcomes resistance to HER2-targeted drugs. Cancer Letters, 2023, 554, 216024.	3.2	4
729	Real-world data of cardiotoxicity during long-term therapy with trastuzumab in human epidermal growth factor receptor-2-positive metastatic breast cancer. Srpski Arhiv Za Celokupno Lekarstvo, 2023, 151, 26-31.	0.1	0
730	Antibody-Drug Conjugates in Breast Cancer: Searching for Magic Bullets. Journal of Clinical Oncology, 2023, 41, 732-735.	0.8	1
731	Treatmentâ€related adverse events of antibodyâ€“drug conjugates in clinical trials: A systematic review and metaâ€analysis. Cancer, 2023, 129, 283-295.	2.0	27
732	Biologic Evaluation of a Heterodimeric HER2-Albumin Targeted Affibody Molecule Produced by Chemo-Enzymatic Peptide Synthesis. Pharmaceutics, 2022, 14, 2519.	2.0	1
733	Gastric Cancer and the Immune System: The Key to Improving Outcomes?. Cancers, 2022, 14, 5940.	1.7	5

#	Article	IF	Citations
734	The evolving therapeutic landscape of antibodyâ€“drug conjugates in breast cancer. Expert Review of Anticancer Therapy, 2022, 22, 1325-1331.	1.1	1
735	Development of therapeutic antibodies for the treatment of diseases. Molecular Biomedicine, 2022, 3, .	1.7	19
736	HER2-Positive Gastroesophageal Cancers Are Associated with a Higher Risk of Brain Metastasis. Cancers, 2022, 14, 5754.	1.7	3
737	â€˜Why is survival with triple negative breast cancer so low? insights and talking points from preclinical and clinical researchâ€™. Expert Opinion on Investigational Drugs, 2022, 31, 1291-1310.	1.9	2
738	Expanding the reach of HER2-targeted therapies: transformation of an historical paradigm. Journal of Clinical Investigation, 2022, 132, .	3.9	0
740	Using theHER2/CEP17FISH Ratio to Predict Pathologic Complete Response Following Neoadjuvant Anti-HER2 Doublet Therapy in HER2+ Breast Cancer. Oncologist, 2023, 28, 123-130.	1.9	2
741	Pitfall in the Surgical Management of a Shrunken Skin Defect after Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer. Case Reports in Oncology, 2022, 15, 1101-1106.	0.3	1
743	New treatment options for metastatic HER2-low breast cancer. , 2023, 44, 53-60.		3
744	Effect of the HER-2/CEP17 ratio in IHC 2+/FISH-amplified breast cancer on pathological complete response to neoadjuvant pertuzumab and trastuzumab treatmentâ€”a retrospective cohort study. Gland Surgery, 2022, 11, 1887-1896.	0.5	0
745	Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer. Nature Communications, 2022, 13, .	5.8	12
746	Advances in antibody-drug conjugates for gynecologic malignancies. Current Opinion in Obstetrics and Gynecology, 0, Publish Ahead of Print, .	0.9	5
747	Retrospective Observational Study of Outcomes in HER2-Positive Metastatic Breast Cancer (mBC) Patients Treated with Ado-Trastuzumab Emtansine (T-DM1) and Subsequent Treatments After T-DM1 in the United States. Drugs - Real World Outcomes, 2023, 10, 177-186.	0.7	1
748	Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet, The, 2023, 401, 105-117.	6.3	144
749	Novel markers in breast pathology. Histopathology, 2023, 82, 119-139.	1.6	1
750	Leveraging Molecular and Immune-Based Therapies in Leptomeningeal Metastases. CNS Drugs, 0, , .	2.7	4
751	Neurologic complications of breast cancer. Cancer, 0, , .	2.0	0
752	Real-World Outcome and Prognostic Factors Among HER2-Positive Metastatic Breast Cancer Patients Receiving Pyrotinib-Based Therapy: A Multicenter Retrospective Analysis. Breast Cancer: Targets and Therapy, 0, Volume 14, 491-504.	1.0	0
753	Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Current and Future Trends. Cancers, 2023, 15, 51.	1.7	6

#	Article	IF	Citations
754	Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): final analysis of a phase III, randomized, double-blind, placebo-controlled study. Breast Cancer Research and Treatment, 2023, 197, 503-513.	1.1	6
755	NEDDylated Cullin 3 mediates the adaptive response to topoisomerase 1 inhibitors. Science Advances, 2022, 8, .	4.7	6
756	Targeting the EGF receptor family in non-small cell lung cancerâ€"increased complexity and future perspectives. Cancer Biology and Medicine, 2022, 19, 1543-1564.	1.4	12
757	Current Standards and Future Outlooks in Metastatic Her2-Positive Breast Cancer. Breast Care, 2023, 18, 69-75.	0.8	4
758	Association of Relative Cerebral Blood Volume from Dynamic Susceptibility Contrast-Enhanced Perfusion MR with HER2 Status in Breast Cancer Brain Metastases. Academic Radiology, 2023, 30, 1816-1822.	1.3	1
759	Additional effect of anthracycline in preoperative chemotherapy with a sequential anthracyclineâ€'containing regimen preceded by pertuzumab, trastuzumab and docetaxel combination therapy. Experimental and Therapeutic Medicine, 2022, 25, .	0.8	0
760	The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer. Cancer Treatment Reviews, 2023, 113, 102500.	3.4	15
761	<scp>EGFR</scp> inhibition in <scp>EGFR</scp>â€mutant lung cancer cells perturbs innate immune signaling pathways in the tumor microenvironment. Cancer Science, 2023, 114, 1270-1283.	1.7	5
762	Combination of radiotherapy and targeted therapy for HER2-positive breast cancer brain metastases. European Journal of Medical Research, 2023, 28, .	0.9	3
763	Adding of apatinib and camrelizumab to overcome de novo trastuzumab resistance of HER2-positive gastric cancer: A case report and literature review. Frontiers in Pharmacology, 0, 13, .	1.6	1
764	Complete Response to Sequential Human Epidermal Growth Factor Receptor 2â€"Targeted Strategies in a Heavily Pretreated Patient With Human Epidermal Growth Factor Receptor 2â€"Amplified Metastatic Bladder Cancer. JCO Precision Oncology, 2023, , .	1.5	1
765	Breast cancer heterogeneity and its implication in personalized precision therapy. Experimental Hematology and Oncology, 2023, 12, .	2.0	31
766	How I treat HER2-low advanced breast cancer. Breast, 2023, 67, 116-123.	0.9	5
767	Interobserver Variation in the Assessment of Immunohistochemistry Expression Levels in HER2-Negative Breast Cancer: Can We Improve the Identification of Low Levels of HER2 Expression by Adjusting the Criteria? An International Interobserver Study. Modern Pathology, 2023, 36, 100009.	2.9	10
768	Clinical best practices in optimal monitoring, early diagnosis, and effective management of antibodyâ€"drug conjugate-induced interstitial lung disease or pneumonitis: a multidisciplinary team approach in Singapore. Expert Opinion on Drug Metabolism and Toxicology, 2022, 18, 805-815.	1.5	3
769	PI3Kâ€"AKT-Targeting Breast Cancer Treatments: Natural Products and Synthetic Compounds. Biomolecules, 2023, 13, 93.	1.8	16
770	Pharmacovigilance Analysis of HeartÂFailure Associated With Anti-HER2 Monotherapies and Combination Regimens for Cancer. JACC: CardioOncology, 2023, 5, 85-98.	1.7	4
771	Outcomes for the first four lines of therapy in patients with HER2-positive advanced breast cancer: results from the SONABRE registry. Breast Cancer Research and Treatment, 0, , .	1.1	2

#	Article	IF	Citations
772	Multi-institutional Assessment of Pathologist Scoring HER2 Immunohistochemistry. Modern Pathology, 2023, 36, 100032.	2.9	19
773	Knowledge atlas of antibody-drug conjugates on CiteSpace and clinical trial visualization analysis. Frontiers in Oncology, 0, 12, .	1.3	6
774	STARD3: A New Biomarker in HER2-Positive Breast Cancer. Cancers, 2023, 15, 362.	1.7	5
775	Trastuzumab emtansine vs lapatinib and capecitabine in HER2-positive metastatic breast cancer brain metastases: A real-world study. Breast, 2023, 69, 441-450.	0.9	2
776	The change of paradigm in the treatment of HER2-positive breast cancer with the development of new generation antibody-drug conjugates. Cancer Drug Resistance (Alhambra, Calif), 2023, 6, 45-58.	0.9	3
777	Antibody-drug conjugates in lung cancer: dawn of a new era?. Npj Precision Oncology, 2023, 7, .	2.3	21
778	HER2-Low Breast Cancer: Incidence, Clinicopathologic Features, and Survival Outcomes From Real-World Data of a Large Nationwide Cohort. Modern Pathology, 2023, 36, 100087.	2.9	9
779	Payload diversification: a key step in the development of antibodyâ€“drug conjugates. Journal of Hematology and Oncology, 2023, 16, .	6.9	42
780	Systemic treatments for breast cancer brain metastasis. Frontiers in Oncology, 0, 12, .	1.3	0
781	Tumor Targeting of ²¹¹At-Labeled Antibody under Sodium Ascorbate Protection against Radiolysis. Molecular Pharmaceutics, 2023, 20, 1156-1167.	2.3	3
782	Molecular Pathways and Mechanisms of HER2 in Cancer Therapy. Clinical Cancer Research, 2023, 29, 2351-2361.	3.2	2
783	Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis. Nature Cancer, 0, , .	5.7	13
784	Phase I study of LZM005 in patients with HER2-positive metastatic breast cancer. Npj Breast Cancer, 2022, 8, .	2.3	1
785	HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1. Journal of the National Cancer Institute, 2023, 115, 332-336.	3.0	6
786	Treatment-related adverse events associated with HER2-Targeted antibody-drug conjugates in clinical trials: a systematic review and meta-analysis. EClinicalMedicine, 2023, 55, 101795.	3.2	7
787	The efficacy of trastuzumab-deruxtecan for the treatment of patients with advanced HER2-low breast cancer. Expert Review of Anticancer Therapy, 0, , 1-8.	1.1	0
788	Next-generation sequencing and molecular therapy. Clinical Medicine, 2023, 23, 65-69.	0.8	2
789	Antibodyâ€“Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer. Cancer Discovery, 2023, 13, 950-973.	7.7	13

#	Article	IF	Citations
790	Bioinformatics combined with clinical data to analyze clinical characteristics and prognosis in patients with HER2 low expression breast cancer. Gland Surgery, 2023, .	0.5	0
791	A potential platform of combining sialic acid derivative-modified paclitaxel cationic liposomes with antibodyâ€“drug conjugates inspires robust tumor-specific immunological memory in solid tumors. Biomaterials Science, 2023, 11, 2787-2808.	2.6	1
792	The HER2-low revolution in breast oncology: steps forward and emerging challenges. Therapeutic Advances in Medical Oncology, 2023, 15, 175883592311528.	1.4	10
793	Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability. Cancers, 2023, 15, 713.	1.7	25
794	HER2-low expression in breast oncology: treatment implications in the smart chemotherapy era. European Journal of Cancer Prevention, 2023, 32, 149-154.	0.6	2
795	Review of the status of neoadjuvant therapy in HER2-positive breast cancer. Frontiers in Oncology, 0, 13, .	1.3	5
796	Clinicopathologic characteristics and prognostic significance of HER2-low expression in patients with early breast cancer: A systematic review and meta-analysis. Frontiers in Oncology, 0, 13, .	1.3	4
797	Emerging Trends in Monoclonal Antibody Therapies Targeting Cancer. , 2023, , 1-48.		0
798	Resistance to Antibody-Drug Conjugates Targeting HER2 in Breast Cancer: Molecular Landscape and Future Challenges. Cancers, 2023, 15, 1130.	1.7	7
799	Predictors of nodal metastases in early stage HER2+ breast cancer: Deciding on treatment approach with neoadjuvant chemotherapy vs. upfront surgery. European Journal of Surgical Oncology, 2023, 49, 1411-1416.	0.5	3
800	New Therapies on the Horizon. Hematology/Oncology Clinics of North America, 2023, , .	0.9	1
801	Transcriptome Meta-Analysis of Triple-Negative Breast Cancer Response to Neoadjuvant Chemotherapy. Cancers, 2023, 15, 2194.	1.7	0
802	ADCs or: How I Learned to Stop Worrying and Love Chemotherapy. Cancer Discovery, 2023, 13, 817-818.	7.7	1
803	Advances in Targeted Therapy of Breast Cancer with Antibody-Drug Conjugate. Pharmaceutics, 2023, 15, 1242.	2.0	5
804	A Phase I Study of a Combination of Liposomal Irinotecan and Veliparib in Solid Tumors. Oncologist, 0, , .	1.9	0
805	Deciphering breast cancer: from biology to the clinic. Cell, 2023, 186, 1708-1728.	13.5	72
806	Survival differences between HER2-0 and HER2-low-expressing breast cancer â^' A meta-analysis of early breast cancer patients. Critical Reviews in Oncology/Hematology, 2023, 185, 103962.	2.0	6
807	Future potential targets of antibody-drug conjugates in breast cancer. Breast, 2023, 69, 312-322.	0.9	2

#	Article	IF	Citations
808	Current Updates in Management of HER2-Positive and HER2-Low Breast Cancer. Current Breast Cancer Reports, 2023, 15, 135-141.	0.5	1
809	Trastuzumab deruxtecan effective in both second-line and neoadjuvant setting. , 0, , .		0
810	Cardiovascular toxicity of tyrosine kinase inhibitors during cancer treatment: Potential involvement of TRPM7. Frontiers in Cardiovascular Medicine, 0, 10, .	1.1	2
811	Digital image analysis and assisted reading of the <scp>HER2</scp> score display reduced concordance: pitfalls in the categorisation of <scp>HER2</scp>â€low breast cancer. Histopathology, 2023, 82, 912-924.	1.6	7
812	Human Epidermal Growth Factor Receptor 2 (HER2) Expression by Immunohistochemistry and Its Clinical Significance in Hepatocellular Carcinoma: A Single-Center Analysis. Cureus, 2023, , .	0.2	1
813	The role of claudin 18.2 and HER-2 in pancreatic cancer outcomes. Medicine (United States), 2023, 102, e32882.	0.4	2
814	HER2 Amplification Level Predicts Pathological Complete Response in the Neoadjuvant Setting of HER2-Overexpressing Breast Cancer: A Meta-Analysis and Systematic Review. International Journal of Molecular Sciences, 2023, 24, 3590.	1.8	3
815	Fam-trastuzumab deruxtecan-nxki (Enhertu^{Â®}): A narrative drug review. Cancer Research Statistics and Treatment, 2022, 5, 701.	0.1	1
816	Prognostic analysis of three forms of Kiâ€67 in patients with breast cancer with nonâ€pathological complete response before and after neoadjuvant systemic treatment. Cancer Medicine, 2023, 12, 9363-9372.	1.3	4
817	Mechanisms of Resistance to Antibodyâ€“Drug Conjugates. Cancers, 2023, 15, 1278.	1.7	10
818	HER2-Directed Therapy in Advanced Breast Cancer: Benefits and Risks. OncoTargets and Therapy, 0, Volume 16, 115-132.	1.0	2
819	De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial. Journal of Clinical Oncology, 2023, 41, 3796-3804.	0.8	7
820	Loss of Rb1 Associated With the Onset of Acquired Resistance to Trastuzumab Deruxtecan in TP53-/HER2-Mutated Nonâ€“Small-Cell Lung Cancer: Case Series. JCO Precision Oncology, 2023, , .	1.5	0
821	Advances in medical treatment of breast cancer in 2022. , 2023, 2, 1-17.		2
822	Unlocking the Resistance to Anti-HER2 Treatments in Breast Cancer: The Issue of HER2 Spatial Distribution. Cancers, 2023, 15, 1385.	1.7	5
823	A Novel Homodimer Peptideâ€“Drug Conjugate Improves the Efficacy of HER2-Positive Breast Cancer Therapy. International Journal of Molecular Sciences, 2023, 24, 4590.	1.8	4
824	A comprehensive regulatory and industry review of modeling and simulation practices in oncology clinical drug development. Journal of Pharmacokinetics and Pharmacodynamics, 2023, 50, 147-172.	0.8	5
826	Antibodyâ€“drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry. Archives of Pharmacal Research, 2023, 46, 131-148.	2.7	18

#	Article	IF	Citations
827	TROP2 expression and SN38 antitumor activity in malignant pleural mesothelioma cells provide a rationale for antibody-drug conjugate therapy. Lung Cancer, 2023, 178, 237-246.	0.9	2
828	Preclinical Efficacy of the Antibodyâ€“Drug Conjugate CLDN6â€“23-ADC for the Treatment of CLDN6-Positive Solid Tumors. Clinical Cancer Research, 2023, 29, 2131-2143.	3.2	3
829	Genetic Code Expansion for Site-Specific Labeling of Antibodies with Radioisotopes. ACS Chemical Biology, 2023, 18, 443-448.	1.6	4
830	Incidence of antibodyâ€“drug conjugates-related pneumonitis in patients with solid tumors: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2023, 184, 103960.	2.0	3
831	HER2-Positive Metastatic Breast Cancer: Available Treatments and Current Developments. Cancers, 2023, 15, 1738.	1.7	6
832	Immunotherapy for HER-2 positive breast cancer. Frontiers in Oncology, 0, 13, .	1.3	8
833	Recent advances in immunotherapy and molecular targeted therapy for gastric cancer. Future Science OA, 2023, 9, .	0.9	2
834	A nationwide observational study in heavily pretreated metastatic HER2-positive breast cancer patients. Acta OncolÃ³gica, 2023, 62, 126-133.	0.8	0
835	Pyrotinib plus capecitabine could significantly improve overall survival in HER2-positive metastatic breast cancer. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	1
836	Target Antigen Attributes and Their Contributions to Clinically Approved Antibody-Drug Conjugates (ADCs) in Haematopoietic and Solid Cancers. Cancers, 2023, 15, 1845.	1.7	9
837	Systemic therapy for hormone receptorâ€positive/human epidermal growth factor receptor 2â€negative early stage and metastatic breast cancer. Ca-A Cancer Journal for Clinicians, 2023, 73, 480-515.	157.7	23
838	Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: a narrative review. Translational Lung Cancer Research, 2023, 12, 615-628.	1.3	6
839	Antibodyâ€“Drug Conjugate Revolution in Breast Cancer: The Road Ahead. Current Treatment Options in Oncology, 2023, 24, 442-465.	1.3	6
840	Combining nanotechnology with monoclonal antibody drugs for rheumatoid arthritis treatments. Journal of Nanobiotechnology, 2023, 21, .	4.2	4
841	Rationale and design of a cardiac safety study for reduced cardiotoxicity surveillance during HER2-targeted therapy. Cardio-Oncology, 2023, 9, .	0.8	2
842	Emerging Targeted Therapies for HER2-Positive Breast Cancer. Cancers, 2023, 15, 1987.	1.7	18
843	Co-Clinical Study of [fam-] Trastuzumab Deruxtecan (DS8201a) in Patient-Derived Xenograft Models of Uterine Carcinosarcoma and Its Association with Clinical Efficacy. Clinical Cancer Research, 2023, 29, 2239-2249.	3.2	4
844	Clinical management of drug-induced cardiotoxicity in patients with HER-2+ breast cancer: current recommendations and future outlook. Expert Opinion on Drug Metabolism and Toxicology, 2023, 19, 109-119.	1.5	1

#	Article	IF	Citations
845	Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2â€“Expressing Advanced or Recurrent Uterine Carcinosarcoma (NCCH1615): The STATICE Trial. Journal of Clinical Oncology, 2023, 41, 2789-2799.	0.8	32
846	Cost-effectiveness and Value-based Pricing of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Low HER2 Expression. Clinical Breast Cancer, 2023, 23, 508-518.	1.1	1
847	Recent trends of characteristics and treatments in adults with newly diagnosed brain metastases. Japanese Journal of Clinical Oncology, 0, , .	0.6	2
848	Precision targeted therapy for <scp>EGFR</scp> mutationâ€positive <scp>NSCLC</scp>: Dilemmas and coping strategies. Thoracic Cancer, 2023, 14, 1121-1134.	0.8	4
849	Antitumor effect of a novel humanized MUC1 antibody-drug conjugate on triple-negative breast cancer. Heliyon, 2023, 9, e15164.	1.4	1
850	HER2 exon 20 insertion mutations and myelosuppression in lung adenocarcinoma patient: a case report and response to trastuzumab deruxtecan. Journal of Cardiothoracic Surgery, 2023, 18, .	0.4	0
851	Multicentre, randomised, double-blind, placebo-controlled phase II study of prophylactic olanzapine for patients with metastatic breast cancer receiving T-DXd treatment: protocol for the ERICA study (WJOG14320B). BMJ Open, 2023, 13, e070304.	0.8	1
853	Emerging Landscape of Targeted Therapy of Breast Cancers With Low Human Epidermal Growth Factor Receptor 2 Protein Expression. Archives of Pathology and Laboratory Medicine, 2024, 148, 242-255.	1.2	3
854	Research trends and prospects on brain metastasis from breast cancer: A bibliometric analysis. Frontiers in Oncology, 0, 13, .	1.3	0
855	Single-arm trials supporting the approval of anticancer medicinal products in the European Union: contextualization of trial results and observed clinical benefit. ESMO Open, 2023, 8, 101209.	2.0	1
856	Comprehensive analysis of a novel RNA modifications-related model in the prognostic characterization, immune landscape and drug therapy of bladder cancer. Frontiers in Genetics, 0, 14, .	1.1	1
857	Comprehensive characterization of HER2-low breast cancers: implications in prognosis and treatment. EBioMedicine, 2023, 91, 104571.	2.7	9
858	Phase I study of A166, an antibodyâ€'drug conjugate in advanced HER2-expressing solid tumours. Npj Breast Cancer, 2023, 9, .	2.3	9
859	High risks adverse events associated with trastuzumab emtansine and trastuzumab deruxtecan for the treatment of HER2-positive/mutated malignancies: a pharmacovigilance study based on the FAERS database. Expert Opinion on Drug Safety, 2023, 22, 685-696.	1.0	1
860	Antibody drug conjugates as targeted cancer therapy: past development, present challenges and future opportunities. Archives of Pharmacal Research, 2023, 46, 361-388.	2.7	9
861	Clinical Significance of ABCG2/BCRP Quantified by Fluorescent Nanoparticles in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy. Cancers, 2023, 15, 2365.	1.7	1
862	Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Antiâ€“Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2â€“Positive Early Breast Cancer. Journal of Clinical Oncology, 2023, 41, 2998-3008.	0.8	14
863	Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. Lancet, The, 2023, 401, 1773-1785.	6.3	58

#	Article	IF	Citations
864	Advancing outcomes of metastatic HER2-positive breast cancer. Lancet, The, 2023, 401, 1746-1747.	6.3	0
865	â€˜Targetingâ€™ Improved Outcomes with Antibody-Drug Conjugates in Non-Small Cell Lung Cancerâ€”An Updated Review. Current Oncology, 2023, 30, 4329-4350.	0.9	1
866	Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics. Pharmaceuticals, 2023, 16, 614.	1.7	18
867	Understanding the activity of antibodyâ€“drug conjugates in primary and secondary brain tumours. Nature Reviews Clinical Oncology, 2023, 20, 372-389.	12.5	18
868	Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics - Open, 0, , .	0.9	0
869	Targeted therapy. , 2023, , 459-488.		0
900	Discovery and development of ADCs: obstacles and opportunities. , 2023, , 75-106.		0
954	Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel. Drug Safety, 2023, 46, 927-949.	1.4	1
972	Can we define breast cancer HER2 status by liquid biopsy?. International Review of Cell and Molecular Biology, 2023, , 23-56.	1.6	2
1035	Molecular Pathology of Breast Tumors. , 2023, , 247-270.		0
1047	A Review of the Current FDA-Approved Antibody-Drug Conjugates: Landmark Clinical Trials and Indications. Pharmaceutical Medicine, 0, , .	1.0	1
1079	Innovative Therapeutic Approaches for Patients with HER2-Positive Breast Cancer. Cancer Treatment and Research, 2023, , 237-281.	0.2	0
1088	New Concepts in Cardio-Oncology. Cancer Treatment and Research, 2023, , 303-341.	0.2	0
1089	Breast Cancer Brain Metastases: Achillesâ€™ Heel in Breast Cancer Patientsâ€™ Care. Cancer Treatment and Research, 2023, , 283-302.	0.2	0
1116	Progress of PD-1/PD-L1 inhibitor combination therapy in immune treatment for HER2-positive tumors. European Journal of Clinical Pharmacology, 2024, 80, 625-638.	0.8	0
1121	Trastuzumab for Active Targeting in Cancer Therapy. , 2024, , 1-30.		0